USRE35279E - Hydantoin derivatives - Google Patents
Hydantoin derivatives Download PDFInfo
- Publication number
- USRE35279E USRE35279E US08/197,705 US19770594A USRE35279E US RE35279 E USRE35279 E US RE35279E US 19770594 A US19770594 A US 19770594A US RE35279 E USRE35279 E US RE35279E
- Authority
- US
- United States
- Prior art keywords
- group
- ylsulfonyl
- substituted
- hydantoin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/76—Sulfur atoms attached to a second hetero atom
- C07D277/80—Sulfur atoms attached to a second hetero atom to a nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel hydantoin derivatives, processes for producing hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.
- Cataract, peripheral neuropathy, retinopathy and nephropathy associated with diabetes mellitus result from abnormal accumulation of polyoi metabolites converted from sugars by aldose reductase.
- sugar cataract results from damage of lens provoked by change in osmotic pressure induced by abnormal accumulation of polyol metabolites converted from glucose or galactose by aldose reductase in lens.
- J. H. Kinoshita et al., Biochim. Biophys. Acta, 158, 472 (1968) and cited references in the report And some reports were submitted about undesirable effect of abnormal accumulation of polyol metabolites in lens, peripheral nerve cord and kidney of the diabetic animals [see A. Pirie et al. Exp.
- An object of the present invention is to provide novel hydantoin derivatives and salts, solvates and solvates of salts thereof.
- Another object of the present invention is to provide processes for producing said novel hydantoin derivatives.
- a further object of the present invention is to provide pharmaceutical compositions comprising at least one of said novel hydantoin derivatives having an inhibitory activity against aldose reductase.
- a further object of the present invention is to provide novel intermediate compounds in the synthesis of said novel hydantoin derivatives.
- sulfonylhydantoin derivatives had a strong inhibitory activity against aidose reductase and accomplished an invention on aldose reductase inhibitors (JP kokai 58 109418, 62 67075, 62 201873 and 1 61465).
- JP kokai 58 109418, 62 67075, 62 201873 and 1 61465) JP kokai 58 109418, 62 67075, 62 201873 and 1 61465.
- M. S. Malamas et al. U.S. Pat. No. 4,743,611 disclosed naphthalenesulfonyl hydantoin derivatives useful as aldose reductase inhibitors.
- Ohishi et al. disclosed benzofuranylsulfonyl glycine derivatives useful as drugs of treatment of diabetic complications (JP Kokai 62 155269).
- the present inventors have made extensive researches on a series of compounds having an inhibitory activity against aldose reductase and found novel hydantoin derivatives having an extremely strong inhibitory activity against aldose reductase. They are extremely usful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
- the present invention is based on the selection of a hydantoin which is bonded by or through a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.
- the present invention is directed to novel hydantoin derivatives represented by the general formula (I): ##STR1## and non-toxic salts, solvates and solvates of non-toxic salts thereof; wherein Q represents an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, a biphenylyl group, a mono- or a fused heterocyclic group which may be substituted by one or more substituents which are same or different and selected from a group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an optionally protected
- the present invention is also directed to the process for preparing above-mentioned hydantoin derivatives.
- the present invention is further directed to pharmaceutical compositions characterized by containing at least one of these hydantoin derivatives as active component(s).
- the present invention is further directed to novel intermediate compounds in the synthesis of above-mentioned hydantoin derivatives.
- Non-toxic salts, solvates and non-toxic salts thereof are free of central nervous system side effects such as anti-convulsant activity and low toxicity, so useful for the treatment and/or prevention of various forms of diabetic complications such as neuropathy, autonomic disease, cataract, retinopathy, neuropathy and microvascular disease.
- the compounds represented by the general formula (I) may form salts with base.
- Typical examples of salts with base of the compounds represented by the general formula (I) include pharmaceutically acceptable salts such as alkali metal salts (such as sodium salts, potassium salts, etc.), alkaline earth metal salts (such as magnesium salts, calcium salts, etc.), salts with organic bases (such as ammonium salts, benzylamine salts, diethylamine salts, etc.) or salts of amino acids (such as arginine salts, lysine salts, etc.).
- These salts of the compounds represented by the general formula (I) may be mono-salts or di-salts which may be salts of the hydantoin moiety and/or salts of the carboxy group contained in the Q group.
- the compounds represented by the general formula (I) may also form acid addition salts.
- Typical example of acid addition salts of the compounds represented by the general formula I) include pharmaceutically acceptable salts, such as salts of inorganic acids (such as hydrochlorides, hydrobromides, sulfates, phosphates, etc.), salts of organic acids (such as acetates, citrates, maleates, tartrates, benzoates, ascorbate, ethanesulfonates, toluene-sulfonates, etc.) or salts of amino acids (such as aspartates, glutamates, etc.).
- These salts of the compounds represented by the general formula (I) may be salts of the heterocyclic moiety in the Q group.
- the lower alkyl group can be defined more specifically as a straight or branched lower alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, isopropyl, tert-butyl, etc.
- the alkoxy group can be defined more specifically as a straight branched lower alkoxy group having 1 to 4 carbon atoms such as methoxy, ethoxy, tert-butoxy, etc.
- the acyl group can be defined more specifically as a straight or branched lower acyl group having 1 to 5 carbon atoms such as formyl, acetyl, propanoyl, butanoyl, pivaloyl, etc.
- the heterocyclic group can be defined as a monocyclic heterocyclic group such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl, thiatriazolyl, thienyl (thiophenyl), furyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, pyridyl or its N-oxide, pyrazinyl, pynmidinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, triazinyl, etc., or a fused heterocyclic group such as indolyl, isoind
- indolyl preferably indolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzothiophenyl, tetrahydrobenzothiophenyl, benzofuranyl, coumarinyl, chromonyl, more preferably benzo[b]thiophenyl or benzo[b]furanyl.
- heterocyclic groups may be substituted with a group such as a lower alkyl group (such as methyl, ethyl, isopropyl, tert-butyl, etc.), a lower alkylcarbonyl group (such as acetyl, propanoyl, butanoyl, etc.), a lower alkoxy group (such as methoxy, ethoxy, isopropoxy, tert-butoxy, etc.), a phenyl group, a cyano group, a carbamoyl group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a nitro group, a halogenated lower alkyl group (such as trifluoromethyl, pentafluoroethyl, etc.), an optionally protected hydroxy group, an optionally protected amino group, (such as acyl amino, etc.), a lower alkylthio group, a lower alkylsulfinyl group
- a compound unsubstituted or substituted with 1 to 3 substituents which are the same or different and selected from a group consisting of a halogen atom, a lower alkyl group, a halogenated lower alkyl group, a lower alkylthio group or a cyano group, is preferable.
- a fused heterocyclic group is a benzo[b]furan-2-yl group which may be substituted
- the said substituents are preferably 1 to 3 halogen atoms.
- the compounds of the present invention represented by the formula (I) can be produced by the processes described as follows.
- a compound Q--H wherein Q has the same significance as defined above and H represents a hydrogen atom is reacted with a base (such as n-butyllithium or lithium diisopropylamide, etc.) and sulfur dioxide and then reacted with a halogenating reagent (such as chlorine, bromine, phosphorus pentachloride, thionyl chloride, N-chlorosuccinimide or N-bromosuccinimide, etc.) to obtain an objective compound.
- a base such as n-butyllithium or lithium diisopropylamide, etc.
- a halogenating reagent such as chlorine, bromine, phosphorus pentachloride, thionyl chloride, N-chlorosuccinimide or N-bromosuccinimide, etc.
- Q--H wherein Q has the same significance as defined above is reacted with a halosulfonic acid (preferably chlorosulfonic acid, etc.) to obtain directly an objective compound.
- a halosulfonic acid preferably chlorosulfonic acid, etc.
- a sulfonic acid derivative of Q--H (Q--SO 3 H) wherein Q has the same significance as defined above is reacted with sodium bicarbonate to give a corresponding salt, and then reacted with a halogenating reagent (such as phosphorus pentachloride, thionyl chloride or thionyl bromide, etc.) to obtain an objective compound.
- a halogenating reagent such as phosphorus pentachloride, thionyl chloride or thionyl bromide, etc.
- an amine derivative of Q--H (Q--NH 2 ) wherein Q has the same significance as defined above is reacted whh a nitrite salt (such as sodium nitrite, etc.), and then reacted with sulfur dioxide and a halogcnating reagent (such as copper (I) chloride or copper (II) chloride, etc.) to obtain an objective compound.
- a nitrite salt such as sodium nitrite, etc.
- sulfur dioxide and a halogcnating reagent such as copper (I) chloride or copper (II) chloride, etc.
- R represents a hydroxy group, an alkoxy group or an amino group which may be substituted by an alkoxycarbonyl group, to give the corresponding sulfonylglycine derivative represented by the formula (IV):
- Such a condensation reaction is carried out generally in an aqueous solution, in an organic solvent (such as dichloromethane, chloroform, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, etc.) or in a mixed solvent of an aqueous solution and an organic solvent, preferably in the presence of deacidifying agent.
- an organic solvent such as dichloromethane, chloroform, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, etc.
- deacidifying agent triethylamine, diethylaniline, pyridine, etc.
- aqueous alkali such as sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, etc.
- the condensation reaction is carried out at temperatures ranging from about -20° to 80° C., preferably 0° C. to room temperature.
- the sulfonylglycine derivative represented by the formula (V) is cyclized using a haloformic acid ester (such as methyl chloroformate, ethyl chloroformate, etc.) in the presence of a base (such as sodium hydride, potassium hydride, butyllithium, etc.) to give the corresponding hydantoin derivative of the present invention represented by the formula (I).
- a haloformic acid ester such as methyl chloroformate, ethyl chloroformate, etc.
- a base such as sodium hydride, potassium hydride, butyllithium, etc.
- the cyclization reaction is carried out generally in an inert solvent (such as N,N-dimethylformamide, dimethylsulfoxide, ethyl ether, tetrahydrofuran, dioxane, dichloromethane, etc.) and at temperatures ranging from about -20° to 120° C., preferably 0° to 80° C.
- an inert solvent such as N,N-dimethylformamide, dimethylsulfoxide, ethyl ether, tetrahydrofuran, dioxane, dichloromethane, etc.
- R represents an amino group protected with an alkoxycarbonyl group
- the sulfonylglycine derivative is cyclized in the presence of a base (such as sodium hydride etc.) to give the corresponding hydantoin derivative of the present invention represented by the formula (I).
- R 1 represents a hydroxy group or an alkoxy group.
- the sulfonylglycine derivative represented by the formula (VI) is cyclized with a thiocyanate derivative (such as ammonium thiocyanate, potassium thiocyanate, etc.) in the presence of an acid anhydride (such as acetic anhydride, propionic anhydride. etc.) and. if necessary and desired, a base (such as pyridine, triethylamine, etc.) to give the corresponding 2-thiohydantoin derivative.
- a thiocyanate derivative such as ammonium thiocyanate, potassium thiocyanate, etc.
- an acid anhydride such as acetic anhydride, propionic anhydride. etc.
- a base such as pyridine, triethylamine, etc.
- the cyclization reaction is carried out after hydrolysis of ester when R 1 represents an alkoxy group.
- the cyclization reaction is carried out generally in an inert solvent (such as pyridine, triethylamine, N,N-dimethylformamide, dimethylsulfoxide, etc.) and at temperatures ranging from 0° to 120° C., preferably room temperature to 100° C.
- an inert solvent such as pyridine, triethylamine, N,N-dimethylformamide, dimethylsulfoxide, etc.
- the 2-thiohydantoin derivative obtained by said cyclization is oxidized using oxidizing agent (such as nitric acid, chlorine, iodine chloride, potassium permanganate, hydrogen peroxide, dimethylsulfoxide-sulfuric acid, etc.) to give the corresponding hydantoin derivatives of the present invention represented by the formula (I).
- the inhibitory activities of hydantoin derivatives on rat lens aldose reductase were measured according to the procedure of Inagaki et al. CK. Inagaki et al., Arch. Biochem. Biophys., 216, 337 (1982)) with slight modifications. Assays were performed in 0.1 M phosphate buffer (pH 6.2) containing 0.4 M ammonium sulfate, 10 mM DL-glyceraldehyde, 0.16 mM nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) and aldose reductase (0.010-0.016 units) in a total volume of 1.0 mi. To this mixture was added 10 ⁇ l of the solution of each hydantoin derivative to be tested, and the decrease in absorbance at 340 nm was measured with a spectrophotometer.
- Hydantom derivatives of the present invention were examined for acute toxicity.
- Groups of 5 ICR strain mice were orally administered with compound 7, 13 to 17, 19, 20, 21, 24, 38, 40, 44, 45, 47 to 49 of the present invention in a dose of 1 g/kg, and no change was observed in any of the groups over the one-week period after the administration.
- compositions containing at least one of these compounds as active component(s) are useful for the treatment and/or prevention of diabetic complication based on the accumlation of polyol metabolites.
- hydantoin derivatives provided by the present invention can be employed as pharmaceutical compositions, for example, in the form of pharmaceutical compositions containing hydantoin derivatives together with appropriate pharmaceutically acceptable carrier or medium such as sterilized water, edible oils, non-toxic organic solvents or non-toxic solubilizer such as glycerin or propylene glycol.
- appropriate pharmaceutically acceptable carrier or medium such as sterilized water, edible oils, non-toxic organic solvents or non-toxic solubilizer such as glycerin or propylene glycol.
- excipients may be mixed with excipients, binders, lubricants, coloring agents, corrigents, emulsifying agents or suspending agents such as Tween 80 or arabic gum to prepare tablets, capsules, powders, granules, subtilized granules, syrups, eye drops, suppositories, ointments, inhalants, aqueous or oily solutions or emulsion or suspensions for injections.
- excipients binders, lubricants, coloring agents, corrigents, emulsifying agents or suspending agents such as Tween 80 or arabic gum to prepare tablets, capsules, powders, granules, subtilized granules, syrups, eye drops, suppositories, ointments, inhalants, aqueous or oily solutions or emulsion or suspensions for injections.
- agents can be administered either orally or parenterally (such as intravenous administration, intramuscular administration, subcutaneous administration, intrarectal administration, percutaneous administration or permucosal administration etc.), and the amount of administration may be in the range of 1 to 3000 mg/day, preferably 10 to 500 rag/day when the preparation is tablets, capsules, powders, injections, suppositories, syrups, inharants or ointments, 1 ⁇ g to 10 mg/day, preferably 10 ⁇ mg to 1 mg/day when the preparation is eye drops, and 1 to 10% composition when the preparation is ointments, and may also be adjusted according to the patient conditions and can administered once or divided 2 to 6 times or by instillation, etc.
- parenterally such as intravenous administration, intramuscular administration, subcutaneous administration, intrarectal administration, percutaneous administration or permucosal administration etc.
- the resultant solution was acidified with 2 N hydrochloric acid to a pH in the range of 1 to 2, and the formed precipitate was separated by filtration to give 33 g of the objective compound.
- Step 2 Anhydrous pyridine (19 ml), ammonium thiocyanate (17 g) and acetic arthydride (50 ml) were added to the product obtained in Step 1 (30 g), and the mixture was heated with stirring on a boiling water bath for 15 minutes. After cooling to room temperature, the resultant solution was poured into ice-water (300 ml), and the formed precipitate was separated by filtration to give 30.6 g of the objective compound.
- Example 6 to 25 prepared in a manner similar to Example 1 are summarized in the following table 3 together with corresponding IR and NMR data and melting points.
- Step 2 Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 2 or Example 1.
- Example 28 to 52 prepared in a manner similar to Example 26 are summarized in the following table 4 together with corresponding IR and NMR data and melting points.
- Example 54 and 55 prepared in a manner similar to Example 53 are summarized in the following table 5 together with corresponding IR and NMR data and melting points.
- aqueous layer was extracted with ethyl acetate (2l) and the combined organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ether and ethyl acetate were removed in vacuo and the residue was triturated with ether to give 146 g of the objective compound.
- the acidified solution was extracted with ethyl acetate (350 ml ⁇ 3), the organic layer was washed with water, then saturated aqueous NaCl solution. and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, the residue was purified by silica-gel column chromatography to give 5.45 g of the objective compound.
- Example 63 to 77 prepared in a manner similar to Example 26 are summarized in the following table 8 together with corresponding IR and NMR data and melting points.
- Example 78 to 81 prepared in a manner similar to Example 53 are summarized in the following table 9 together with corresponding IR and NMR data and melting points.
- Example 82 and 83 prepared in a manner similar to Example 61 are summarized in the following table 10 together with corresponding IR and NMR data and melting points.
- Example 82 To a suspension of the product obtained in Example 82 (0.65 g) in dichloromethanc (26 ml) was added m-chloroperbenzoic acid (0.41 g) and the mixture was stirred for 1.5 hours at room temperature. The resulting solution was concentrated in vacuo and the residue was washed with ether (30 ml). The residue was purified by silica gel column chromatography to give 0.48 g of the objective compound.
- Example 82 To a suspension of the product obtained in Example 82 (0.65 g) in ethyl acetate (26 ml) was added m-chloroperbenzoic acid (0.82 g) and the mixture was stirred under reflux for 1.5 hours. Additional m-chloroperbenzoic acid (0.16 g) was added and the mixture was stirred under reflux for more 1.5 hours. The resulting solution was concentrated in vacuo and the residue was washed with successive methanol and ether to give 0.40 g of the objective compound.
- Example 67 To a mixture of the product obtained in Example 67 (11.3 g) and copper (I) cyanide (4.1 g) was added pyridine (42 ml). After stirring at 70° C. for 17 hours, a solution of Iron (IIl) chloride hexahydrate (15.7 g) in concentrated hydrochloric acid (3.9 ml) and water (23.6 ml) was added slowly to the solution and the resultant mixture was heated with stirring for 5 minutes at 50° C. The formed precipitate was separated by filtration and the filtrate was extracted with ethyl acetate (300 ml) and the organic layer was washed with successive water and saturated aqueous NaCl solution and dried over anhydrous sodium sulfate. Above mentioned precipitate was extracted by ethanol and this ethanol solution was combined with above mentioned organic layer. The resulting solution was concentrated in vacuo and purified by silica gel column chromatography to give 1.21 g of the objective compound.
- Example 87 A mixture of the product obtained in Example 87 (0.84 g) and 80% (v/v) sulfuric acid (16.3 ml) was heated with stirring for 8 hours at 70° C. and the resulting solution was poured into ice-water (200 ml). The formed precipitate was separated by filtration and washed with successive water, ethanol and acetone to give 0.16 g of the objective compound.
- Example 89 To a suspension of the product obtained in Example 89 (0.60 g) in concentrated sulfuric acid (18 ml) was added sodium nitrite (2.4 g) under cooling at -15° C. and the resulting suspension was stirred for 15 minutes at -15° C., for 30 minutes at 0° C. and for 50 minutes at room temperaiure. To the mixture was added additional sodium nitrite (1.2 g) and stirred for 30 minutes at room temperature. After adjusting a pH of the resulting solution to ca. 9 with 0.1 M sodium bicarbonate, the resulting solution was washed with ethyl acetate and acidified with concentrated hydrochloric acid to a pH about 2 and extracted with ethyl acetate (200 ml).
- Example 97 to 102 prepared in a manner similar to Example 91 are summarized in the following table 11 together with corresponding IR, and NMR data and melting points.
- Example 29 to 39, 41 to 48, 50, 52, 54, 63 to 83, 97 to 102 are summarized in the following table 12 to 16 together with corresponding IR and NMR data and melting points.
- Compound 38 250 g of weight, 730 g of lactose and 20 g of magnesium stearate were weighed and mixed until the mixture became homogeneous. The mixture was then filled in No. 1 hard gelatin capsule at 200 mg each to obtain capsule preparation.
- Compound 34 300 g of weight, 550 g of lactose, 120 g of potato starch, 15 of polyvinyl alcohol and 15 g of magnesium stearate were weighed. The weighed amount of compound 34, lactose and potato starch were mixed until accomplishing homogeneity. Then aqueous solution of polyvinylalcohol was added to the mixture and granulated by wet process. The granules were then dried, mixed with magnesium stearate and pressed into tablets, each weighing 200 mg.
- Compound 46 200 g of weight, 790 g of lactose and 10 g of magnesium stearate were weighed and mixed until the mixture became homogeneous to obtain 20% powder preparation.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.
The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.
The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
Description
This is a divisional application of U.S. Ser. No. 07/426,021 filed Oct. 24, 1989, now U.S. Pat. No. 5,004,751 which in turn was a continuation-in-part divisional application of U.S. Ser. No. 07/235,557, filed Aug. 24, 1988, now U.S. Pat. No. 4,914,099.
The present invention relates to novel hydantoin derivatives, processes for producing hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.
Cataract, peripheral neuropathy, retinopathy and nephropathy associated with diabetes mellitus result from abnormal accumulation of polyoi metabolites converted from sugars by aldose reductase. For example, sugar cataract results from damage of lens provoked by change in osmotic pressure induced by abnormal accumulation of polyol metabolites converted from glucose or galactose by aldose reductase in lens. [see J. H. Kinoshita et al., Biochim. Biophys. Acta, 158, 472 (1968) and cited references in the report]. And some reports were submitted about undesirable effect of abnormal accumulation of polyol metabolites in lens, peripheral nerve cord and kidney of the diabetic animals [see A. Pirie et al. Exp. Eye Res., 3, 124 (1964) L. T. Chylack Jr. et at., Invest. Opthal., 8,401 (1969) J. D. Ward el al, Diabetologia, 6, 531 (1970)]. Consequently, it is important to inhibit aldose reductase as strongly as possible for treating and/or preventing diabetic complications mentioned above. Although several compounds have been offered as aldose reductase inhibitors, none of them is fully sufficient in inhibitory activity against the enzyme. Therefore, it has been desired to develop new compounds having a stronger inhibitory activity against aldose reduetase.
An object of the present invention is to provide novel hydantoin derivatives and salts, solvates and solvates of salts thereof.
Another object of the present invention is to provide processes for producing said novel hydantoin derivatives.
A further object of the present invention is to provide pharmaceutical compositions comprising at least one of said novel hydantoin derivatives having an inhibitory activity against aldose reductase.
A further object of the present invention is to provide novel intermediate compounds in the synthesis of said novel hydantoin derivatives.
The present inventors previously found that substituted phenylsulfonylhydantoin derivatives and naphthalenylsulfonylhydantoin derivatives had a strong inhibitory activity against aldose reductase and accomplished an invention on aldore reductase inhibitors. (JP-A-56 213518, 60 207113, 61 43770)
The present inventors previously found that sulfonylhydantoin derivatives had a strong inhibitory activity against aidose reductase and accomplished an invention on aldose reductase inhibitors (JP kokai 58 109418, 62 67075, 62 201873 and 1 61465). And M. S. Malamas et al. U.S. Pat. No. 4,743,611 disclosed naphthalenesulfonyl hydantoin derivatives useful as aldose reductase inhibitors. And Ohishi et al. disclosed benzofuranylsulfonyl glycine derivatives useful as drugs of treatment of diabetic complications (JP Kokai 62 155269).
Furthermore, the present inventors have made extensive researches on a series of compounds having an inhibitory activity against aldose reductase and found novel hydantoin derivatives having an extremely strong inhibitory activity against aldose reductase. They are extremely usful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.
As a result of extensive investigations concerning development of hydantoin derivatives having a satisfactory inhibitory activity against aldose reductase, the present inventors have found that novel hydantoin derivatives represented by the general formula (I) satisfy this requirement and have accomplished the present invention.
The present invention is based on the selection of a hydantoin which is bonded by or through a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.
The present invention is directed to novel hydantoin derivatives represented by the general formula (I): ##STR1## and non-toxic salts, solvates and solvates of non-toxic salts thereof; wherein Q represents an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, a biphenylyl group, a mono- or a fused heterocyclic group which may be substituted by one or more substituents which are same or different and selected from a group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an optionally protected hydroxy group, an optionally protected amino group, a carbamoyi group and a phenyl group or a group: ##STR2## wherein R1 represents an andno group which may be substituted with lower alkyl groups and/or acyl groups, a halogen atom, a lower alkyl group, an alkoxy group, a nitro group or a cyano group, or combination of any of these groups when n represents an integer of 2 or more, and n represents an integer of 1, 2, 3 or 4.
The present invention is also directed to the process for preparing above-mentioned hydantoin derivatives.
The present invention is further directed to pharmaceutical compositions characterized by containing at least one of these hydantoin derivatives as active component(s).
The present invention is further directed to novel intermediate compounds in the synthesis of above-mentioned hydantoin derivatives.
Compounds of the present invention and non-toxic salts, solvates and solvates or non-toxic salts thereof represents a satisfactory inhibitory activity against aldose reductase and a preventing activity against cataracts, neuropathy in experimental animal models.
Compounds of the present invention and non-toxic salts, solvates and non-toxic salts thereof are free of central nervous system side effects such as anti-convulsant activity and low toxicity, so useful for the treatment and/or prevention of various forms of diabetic complications such as neuropathy, autonomic disease, cataract, retinopathy, neuropathy and microvascular disease.
In the hydantoin derivatives of the present invention represented by the general formula (I), it is known that the hydantoin moiety exhibits tautomerism as shown below: ##STR3##
Since these tautomeric isomers are generally deemed to be the same substance, the compounds of the present invention represented by the general formula (I) also include all of these tautomeric isomers.
The compounds represented by the general formula (I) may form salts with base. Typical examples of salts with base of the compounds represented by the general formula (I) include pharmaceutically acceptable salts such as alkali metal salts (such as sodium salts, potassium salts, etc.), alkaline earth metal salts (such as magnesium salts, calcium salts, etc.), salts with organic bases (such as ammonium salts, benzylamine salts, diethylamine salts, etc.) or salts of amino acids (such as arginine salts, lysine salts, etc.). These salts of the compounds represented by the general formula (I) may be mono-salts or di-salts which may be salts of the hydantoin moiety and/or salts of the carboxy group contained in the Q group.
The compounds represented by the general formula (I) may also form acid addition salts. Typical example of acid addition salts of the compounds represented by the general formula I) include pharmaceutically acceptable salts, such as salts of inorganic acids (such as hydrochlorides, hydrobromides, sulfates, phosphates, etc.), salts of organic acids (such as acetates, citrates, maleates, tartrates, benzoates, ascorbate, ethanesulfonates, toluene-sulfonates, etc.) or salts of amino acids (such as aspartates, glutamates, etc.). These salts of the compounds represented by the general formula (I) may be salts of the heterocyclic moiety in the Q group.
In the compounds of the present invention represented by the general formula (I), the lower alkyl group can be defined more specifically as a straight or branched lower alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, isopropyl, tert-butyl, etc. The alkoxy group can be defined more specifically as a straight branched lower alkoxy group having 1 to 4 carbon atoms such as methoxy, ethoxy, tert-butoxy, etc. The acyl group can be defined more specifically as a straight or branched lower acyl group having 1 to 5 carbon atoms such as formyl, acetyl, propanoyl, butanoyl, pivaloyl, etc.
In the compounds of the present invention represented by the general formula (I), the heterocyclic group can be defined as a monocyclic heterocyclic group such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl, thiatriazolyl, thienyl (thiophenyl), furyl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, pyridyl or its N-oxide, pyrazinyl, pynmidinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, triazinyl, etc., or a fused heterocyclic group such as indolyl, isoindolyl, benzimidazolyl, quinolyl, isoquinolyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, indazolyl, benzotriazolyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzisoxazolyl, benzisothiazolyl, benzothiophenyl (benzo[b]thiophenyl or benzo[c]thiophenyl)-(benzothienyl (benzo[b]thienyl or benzo[c]thienyl)), tetrahydrobenzothiophenyl (tetrahydrobenzothienyl), benzofuranyl (benzo[b]furanyl or isobenzofuranyl), chromenyl, chromanyl, coumarinyl, chromonyl, triazolopyridyl, tetrazolopyridyl, purinyl, thiazolopyrimidinyl, triazolopyrimidinyl, thiadiazolopyrmidinyl, thiazolopyridazinyl, naphthyridinyl, xanthenyl, phenoxathiinyl, phenoxazinyl, phenothiazinyl, carbazolyl, etc. preferably indolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzothiophenyl, tetrahydrobenzothiophenyl, benzofuranyl, coumarinyl, chromonyl, more preferably benzo[b]thiophenyl or benzo[b]furanyl. The above-mentioned heterocyclic groups may be substituted with a group such as a lower alkyl group (such as methyl, ethyl, isopropyl, tert-butyl, etc.), a lower alkylcarbonyl group (such as acetyl, propanoyl, butanoyl, etc.), a lower alkoxy group (such as methoxy, ethoxy, isopropoxy, tert-butoxy, etc.), a phenyl group, a cyano group, a carbamoyl group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a nitro group, a halogenated lower alkyl group (such as trifluoromethyl, pentafluoroethyl, etc.), an optionally protected hydroxy group, an optionally protected amino group, (such as acyl amino, etc.), a lower alkylthio group, a lower alkylsulfinyl group, a lower alkyl sulfonyl group or a halogen atom (such as fluoro, chloro, bromo, iodo etc.), or combination of any of these groups.
In a mono- heterocyclic group, a compound unsubstituted or substituted with 1 or 2 substituents which are the same or different and selected from a group consisting of a halogen atom or phenyl group, is preferable.
In a fused heterocyclic group, a compound unsubstituted or substituted with 1 to 3 substituents which are the same or different and selected from a group consisting of a halogen atom, a lower alkyl group, a halogenated lower alkyl group, a lower alkylthio group or a cyano group, is preferable.
When a fused heterocyclic group is a benzo[b]furan-2-yl group which may be substituted, the said substituents are preferably 1 to 3 halogen atoms.
The compounds of the present invention represented by the formula (I) can be produced by the processes described as follows.
Namely,
The starting material of sulfonyl halide represented by the formula (II):
Q--SO.sub.2 --Y (II)
wherein Q has the same significance as defined above, and Y represents a halogen atom, is prepared as follows.
A compound Q--H wherein Q has the same significance as defined above and H represents a hydrogen atom is reacted with a base (such as n-butyllithium or lithium diisopropylamide, etc.) and sulfur dioxide and then reacted with a halogenating reagent (such as chlorine, bromine, phosphorus pentachloride, thionyl chloride, N-chlorosuccinimide or N-bromosuccinimide, etc.) to obtain an objective compound.
Further, Q--H wherein Q has the same significance as defined above is reacted with a halosulfonic acid (preferably chlorosulfonic acid, etc.) to obtain directly an objective compound.
Further, a sulfonic acid derivative of Q--H (Q--SO3 H) wherein Q has the same significance as defined above is reacted with sodium bicarbonate to give a corresponding salt, and then reacted with a halogenating reagent (such as phosphorus pentachloride, thionyl chloride or thionyl bromide, etc.) to obtain an objective compound.
Further, a S-benzyl derivative of Q--H (Q--S--CH2 C6 H5) wherein Q has the same significance as defined above is reacted with a halogenating reagent (such as chlorine, etc.) to obtain an objective compound.
Further, an amine derivative of Q--H (Q--NH2) wherein Q has the same significance as defined above is reacted whh a nitrite salt (such as sodium nitrite, etc.), and then reacted with sulfur dioxide and a halogcnating reagent (such as copper (I) chloride or copper (II) chloride, etc.) to obtain an objective compound.
The sulfonyl halide derivative, obtained above mentioned procedure is reacted with a glycine derivative represented by the formula (III):
NH.sub.2 CH.sub.2 CO--R (III)
wherein R represents a hydroxy group, an alkoxy group or an amino group which may be substituted by an alkoxycarbonyl group, to give the corresponding sulfonylglycine derivative represented by the formula (IV):
Q--SO.sub.2 NHCH.sub.2 CO--R (IV)
wherein Q and R have the same significance as defined above. Such a condensation reaction is carried out generally in an aqueous solution, in an organic solvent (such as dichloromethane, chloroform, dioxane, tetrahydrofuran, acetonitrile, ethyl acetate, acetone, N,N-dimethylformamide, etc.) or in a mixed solvent of an aqueous solution and an organic solvent, preferably in the presence of deacidifying agent. As the deacidifying agent, triethylamine, diethylaniline, pyridine, etc. is employed in the organic solvent system, and in the aqueous system, aqueous alkali (such as sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, etc.) is employed. The condensation reaction is carried out at temperatures ranging from about -20° to 80° C., preferably 0° C. to room temperature.
When R represents an amino group in the formula (IV), the sulfonylglycine derivative is represented by the formula (V):
Q--SO.sub.2 NHCH.sub.2 CONH.sub.2 (V)
wherein Q has the same significance as defined above.
The sulfonylglycine derivative represented by the formula (V) is cyclized using a haloformic acid ester (such as methyl chloroformate, ethyl chloroformate, etc.) in the presence of a base (such as sodium hydride, potassium hydride, butyllithium, etc.) to give the corresponding hydantoin derivative of the present invention represented by the formula (I). The cyclization reaction is carried out generally in an inert solvent (such as N,N-dimethylformamide, dimethylsulfoxide, ethyl ether, tetrahydrofuran, dioxane, dichloromethane, etc.) and at temperatures ranging from about -20° to 120° C., preferably 0° to 80° C.
When R represents an amino group protected with an alkoxycarbonyl group, the sulfonylglycine derivative is cyclized in the presence of a base (such as sodium hydride etc.) to give the corresponding hydantoin derivative of the present invention represented by the formula (I).
When R represents a hydroxy group or an alkoxy group in the formula (IV), the sulfonylglycine derivative is represented by the formula (VI):
Q--SO.sub.2 NHCH.sub.2 CO--R.sup.1 (VI)
wherein Q has the same significance as defined above and R1 represents a hydroxy group or an alkoxy group. The sulfonylglycine derivative represented by the formula (VI) is cyclized with a thiocyanate derivative (such as ammonium thiocyanate, potassium thiocyanate, etc.) in the presence of an acid anhydride (such as acetic anhydride, propionic anhydride. etc.) and. if necessary and desired, a base (such as pyridine, triethylamine, etc.) to give the corresponding 2-thiohydantoin derivative. If necessary and desired, the cyclization reaction is carried out after hydrolysis of ester when R1 represents an alkoxy group. The cyclization reaction is carried out generally in an inert solvent (such as pyridine, triethylamine, N,N-dimethylformamide, dimethylsulfoxide, etc.) and at temperatures ranging from 0° to 120° C., preferably room temperature to 100° C. Further, the 2-thiohydantoin derivative obtained by said cyclization is oxidized using oxidizing agent (such as nitric acid, chlorine, iodine chloride, potassium permanganate, hydrogen peroxide, dimethylsulfoxide-sulfuric acid, etc.) to give the corresponding hydantoin derivatives of the present invention represented by the formula (I).
To demonstrate the utility of the compounds of the present invention, experimental examples of representative compounds are shown below.
Compounds in the present invention
Compound 1: 1-(1-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 2: 1-(3-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 3: 1-(5-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 4: 1-(6-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 5: 1-(7-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 6: 1-(8-chloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 7: 1-(3,6-dichloronaphthalen-2-ylsulfonyl)-hydantoin
Compound 8: 1-(1-bromonaphthalen-2-ylsulfonyl)-hydantoin
Compound 9: 1-(3-bromonaphthalen-2-ylsulfonyl)-hydantoin
Compound 10: 1-(6-bromonaphthalen-2-ylsulfonyl)-hydantoin
Compound 11: 1-(5-nitronaphthalen-2-ylsulfonyl)-hydantoin
Compound 12: 1-(3-methylnaphthalen-2-ylsulfonyl)-hydantoin
Compound 13: 1-(6-methyl-5-nitronaphthalen-2-ylsulfonyl)hydantoin
Compound 14: 1-(7-methylnaphthalen-2-ylsulfonyl)-hydantoin
Compound 15: 1-(6-methoxy-5-nitronaphthalen-2-ylsulfonyl)hydantoin
Compound 16: 1-(benzo[b]thiophen-2-ylsulfonyl)-hydantoin
Compound 17: 1-(3-chlorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 18: 1-(5-chlorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 19: 1-(benzo[b]furan-2-ylsulfonyl)hydantoin
Compound 20: 1-(5-chlorobenzo[b]furan-2-ylsulfonyl)-hydantoin
Compound 21: 1-(5-bromobenzo[b]furan-2-ylsulfonyl)-hydantoin
Compound 22: 1-(benzothiazol-2-ylsulfonyl)hydantoin
Compound 23: 1-(coumarin-6-ylsulfonyl)hydantoin
Compound 24: 1-(2,5-dichlorothiophen-3-ylsulfonyl)-hydantoin
Compound 25: 1-(4,5-dibromothiophen-2-ylsulfonyl)-hydantoin
Compound 26: 1-(6-chlorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 27: 1-(7-chlorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 28: 1-(3-isopropylbenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 29: 1-(3-trifluoromethylbenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 30: 1-(3-bromobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 31: 1-(3-methoxybenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 32: 1-(3-methylsulfonylbenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 33: 1-(3-cyanobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 34: 1-(3-bromo-7-fluorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 35: 1-(2-chlorobenzo[b]thiophen-3-ylsulfonyl)hydantoin
Compound 36: 1-(4-iodobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 37: 1-(4,6-dichlorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 38: 1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 39: 1-(5-fluorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 40: 1-(4-chlorobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 41: 1-(benzo[b]isothiazol-3-ylsulfonyl)hydantoin
Compound 42: 1-(5-nitrobenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 43: 1-(5-carboxybenzo[b]thiophen-2-ylsulfonyl)hydantoin
Compound 44: 1-(4,5-dichlorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 45: 1-(5,6-dichlorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 46: 1-(3-bromo-4,6-dichlorobertzo[b]furan-2-ylsulfonyl)hydantoin
Compound 47: 1-(3-chlorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 48: 1-(7-fluorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound 49: 1-(3-bromo-7-fluorobenzo[b]furan-2-ylsulfonyl)hydantoin
Compound A: 1-(naphthalene-2-ylsulfonyl)hydantoin
Compound B: sorbinil: [(S)-6-Fluoro-2,3-dihydrospiro(4H-1-benzopyran4,4'-imidazolidine)-2', 5'-dione] (synthesized by the method of R. S. sarges et al.: see J. Med. Chem., 28, 1716 (1985))
The inhibitory activities of hydantoin derivatives on rat lens aldose reductase were measured according to the procedure of Inagaki et al. CK. Inagaki et al., Arch. Biochem. Biophys., 216, 337 (1982)) with slight modifications. Assays were performed in 0.1 M phosphate buffer (pH 6.2) containing 0.4 M ammonium sulfate, 10 mM DL-glyceraldehyde, 0.16 mM nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) and aldose reductase (0.010-0.016 units) in a total volume of 1.0 mi. To this mixture was added 10 μl of the solution of each hydantoin derivative to be tested, and the decrease in absorbance at 340 nm was measured with a spectrophotometer.
The concentrations of typical hydantoin derivatives of the present invention required to produce 50% inhibition are shown in table 1.
TABLE 1
______________________________________
Compounds
IC.sub.50 (μmol/l)
______________________________________
1 0.29
2 0.16
3 0.19
4 0.14
5 0.39
6 0.46
7 0.24
8 0.094
9 0.35
10 0.17
11 0.10
12 0.14
13 0.027
14 0.35
15 0.038
A 0.66
______________________________________
The inhibitory activities of hydantoin derivatives on bovine lens aldose rcductase were measured according to the procedure of Inagaki et al. (K. Inagaki et al., Arch. Blochcm. Biophys., 216, 337 (1982)) with slight modifications. Assay procedure was the same as described in Experimental example 1 except that bovine lens aldose reductsse preparation was used instead of rat lens aldose reductase preparation.
The concentrations of the typical hydantoin derivatives of the present invention required to produce 50% inhibition are shown in table 2.
TABLE 2 ______________________________________ Compounds IC.sub.50 (μmol/l) ______________________________________ 13 0.10 15 0.23 16 0.39 17 0.12 18 0.24 20 0.36 21 0.30 22 0.34 23 0.22 24 0.29 25 0.26 26 0.27 27 0.19 28 0.14 29 0.13 30 0.12 31 0.27 32 0.38 33 0.19 34 0.085 35 0.30 36 0.24 37 0.17 38 0.16 39 0.32 40 0.17 41 0.47 42 0.27 43 0.40 44 0.061 45 0.083 46 0.054 B 0.65 ______________________________________
Compounds 13, 15, 16 to 18, 20 to 46 of the present invention showed stronger inhibitory activities against aldose reductase than reference compound B did, which is a well known potent aldose reductase inhibitor. Compound 17, 18, 23 and 24 were as potent as compound 13 and 15, which showed strongest inhibitory activities in experimental example 1. Above all, several compounds were ten times or more potent than reference compound B.
Hydantom derivatives of the present invention were examined for acute toxicity. Groups of 5 ICR strain mice were orally administered with compound 7, 13 to 17, 19, 20, 21, 24, 38, 40, 44, 45, 47 to 49 of the present invention in a dose of 1 g/kg, and no change was observed in any of the groups over the one-week period after the administration.
Since the compounds of the present invention have strong inhibitory activities against aldose reductase, show lower toxicity and show stronger preventing activities against cataracts, neuropathy in animal models than known compounds, pharmaceutical compositions containing at least one of these compounds as active component(s) are useful for the treatment and/or prevention of diabetic complication based on the accumlation of polyol metabolites.
The hydantoin derivatives provided by the present invention can be employed as pharmaceutical compositions, for example, in the form of pharmaceutical compositions containing hydantoin derivatives together with appropriate pharmaceutically acceptable carrier or medium such as sterilized water, edible oils, non-toxic organic solvents or non-toxic solubilizer such as glycerin or propylene glycol. They may be mixed with excipients, binders, lubricants, coloring agents, corrigents, emulsifying agents or suspending agents such as Tween 80 or arabic gum to prepare tablets, capsules, powders, granules, subtilized granules, syrups, eye drops, suppositories, ointments, inhalants, aqueous or oily solutions or emulsion or suspensions for injections. These agents can be administered either orally or parenterally (such as intravenous administration, intramuscular administration, subcutaneous administration, intrarectal administration, percutaneous administration or permucosal administration etc.), and the amount of administration may be in the range of 1 to 3000 mg/day, preferably 10 to 500 rag/day when the preparation is tablets, capsules, powders, injections, suppositories, syrups, inharants or ointments, 1 μg to 10 mg/day, preferably 10 μmg to 1 mg/day when the preparation is eye drops, and 1 to 10% composition when the preparation is ointments, and may also be adjusted according to the patient conditions and can administered once or divided 2 to 6 times or by instillation, etc.
Hereafter the present invention will be described with references to the examples below but is not deemed to be limited thereof.
To a solution of potassium carbonate (21 g) and glycine (11 g) in water (300 ml) was added 1-chloronaphthalen-2-ylsulfonyl chloride (31 g) at room temperature, and the mixture was stirred under reflux for 30 minutes.
After cooling to room temperature, the resultant solution was acidified with 2 N hydrochloric acid to a pH in the range of 1 to 2, and the formed precipitate was separated by filtration to give 33 g of the objective compound.
Melting point: 185.5°-200.7° C.
IR (KBr, cm-1): 3380, 1720, 1325, 1135
NMR (DMSO-d6, ppm): 3.63 (2H, s), 7.59-8.51 (7H, m)
Anhydrous pyridine (19 ml), ammonium thiocyanate (17 g) and acetic arthydride (50 ml) were added to the product obtained in Step 1 (30 g), and the mixture was heated with stirring on a boiling water bath for 15 minutes. After cooling to room temperature, the resultant solution was poured into ice-water (300 ml), and the formed precipitate was separated by filtration to give 30.6 g of the objective compound.
Melting point: 268.6° C. (decomposition)
IR (KBr, cm-1 : 3150, 1790, 1765, 1380, 1190
NMR (DMSO-d6, ppm): 4.93 (2H, s), 7.66-8.53 (5H, m), 8.78 (1H, s)
A mixture of the product obtained in Step 2 (20 g) and 50% (w/v, nitric acid (100 ml) was heated with stirring on a boiling water bath for 40 minutes, and the resultant solution was cooled in an ice bath. The formed precipitate was separated by filtration and washed successively with water, ethyl alcohol, methyl alcohol and dichloromethane to give 4.8 g of the objective compound.
Melting point: 258.3°-260.5° C.
IR (KBr, cm-1): 3140, 1740, 1310, 1180
NMR (DMSO-d6, ppm): 4.74 (2H, s), 7.80-8.39 (6H, m), 11.77 (1H, s)
Starting from 1-bromonaphthalen-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 of Example 1.
Melting point: 199.7°-204.1° C.
NMR (DMSO-d6, ppm): 3.77 (2H, d, J=6.0 Hz), 7.49-8.47 (7H, m)
Starting from the product obtained in Step 1, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 253.7° C. (decomposition)
NMR (DMSO-d6, ppm): 5.01 (2H, s), 7.71-8.80 (6H, m)
A mixture of the product obtained in Step 2 (7.5 g) and 50% (w/v) nitric acid (50 ml) was heated with stirring on a boiling water bath for 30 minutes and 60% (w/v) nitric acid (25 ml) was added. The reaction mixture was heated with stirring on a boiling water bath for 2 hours. The resultant solution was cooled in an ice bath, and the formed precipitate was sepanted by filtration and washed successively with water, methyl alcohol and dichloromethane to give 2.7 g of the objective compound.
Melting point: 287.4-292.5° C.
IR (KBr, cm-1): 3200, 1740, 1310, 1180
NMR (DMSO-d6, ppm): 4.78 (2H, s), 7.79-8.52 (6H, m), 11.75 (1H, s)
To a solution of potassium carbonate (11.7 g) and glycine (6.4 g) in water (140 ml) were added 3,6-dichloronaphthalen-2-ylsulfonyl chloride (20.8 g) and dioxane (50 ml) at room temperature, and the mixture was stirred under reflux for 2 hours. After cooling to room temperature, the resultant solution was acidified with 2N hydrochloric acid to a pH in the range of 1 to 2, and extracted with ethyl acetate. The organic layer was washed with water, then with saturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo to give 19.0 g of the objective compound.
Melting point: 185.0°-188.2° C.
NMR (DMSO-d6, ppm): 3.82 (2H, d, J=8.0 Hz), 7.49-8.34 (5H, m), 8.63 (1H, s)
Starting from the product obtained in Step 1, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 252.8° C. (decomposition)
NMR (DMSO-d6, ppm): 4.92 (2H, s), 7.38-8.32 (4H, m), 8.90 (1H, s)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 3 of Example 1.
Melting point: 263.1°-266.5° C.
IR (KBr, cm-1): 3220, 1740, 1355, 1170
NMR (DMSO-d6, ppm): 4.67 (2H, s). 7.74 (1H, d), 8.18-8.43 (3H, m), 8.98 (1H, s), 11.77 (1H, bs)
To a solution of potassium carbonate (3.2 g) and glycine (1.7 g) in water (50 ml) was added 5-nitronaphthalen-2-ylsulfonyl chloride (5 g) at room temperature, and the mixture was stirred under reflux for 5 minutes. After cooling to room temperature, the resultant solution was acidified with 2N hydrochloric acid to a pH in the range of 1 to 2, and the formed precipitate was separated by filtration to give 5.4 g of the objective compound.
Melting point: 235.7°-240.7° C.
IR (KBr, cm-1): 3353, 1718, 1519, 1335, 1143
NMR (DMSO-d6, ppm): 3.70 (2H, d, J=5.9 Hz), 7.73-8.64 (7H, m), 12.60 (1H, bs)
Starting from the product obtained in Step 1, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 249.6°-254.8° C.
IR (KBr, cm-1): 3303, 1794, 1767, 1519, 1453, 1343, 1163
NMR (DMSO-d6, ppm): 4.88 (2H, s), 7.8C-9.03 (6H, m), 12.67 (1H, bs)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 3 of Example 1.
Melting point: 241.6°-245.6° C.
IR (KBr, cm-1): 3265, 1801, 1737, 1523, 1340 1170
NMR (DMSO-d6, ppm): 4.58 (2H, s), 7.81-8.96 (6H, m), 11.64 (1H, bs)
Starting from 6-acetamidonaphthalen-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 of Example 1.
Melting point: 202.2°-204.0° C.
NMR (DMSO-d6, ppm): 2.11 (3H, s), 3.36 (2H, s), 5.01 (1H, bs), 7.58-8.40 (7H, m), 10.38 (1H, bs)
Starting from the product obtained in Step 1, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 274.0°-276.9° C.
NMR (DMSO-d6, ppm): 2.13 (3H, s), 4.85 (2H, s), 7.74-8.65 (6H, m), 10.30 (1H, s), 12.60 (1H, bs)
To a mixture of the product obtained in Step 2 (1.45 g), sodium bicarbonate (16 g), carbon tetrachloride (40 ml) and water (120 ml) was added slowly a solution of iodine monochloride (6.9 ml) in 1N hydrochloric acid (40 ml) at room temperature. After stirring at room temperature for 10 minutes, 6N hydrochloric acid (320 ml) was added, and the resultant solution was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium sulfite solution, then with saturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, and the residue was washed with dichloromethane to give 1.0 g of the objective compound.
Melting point: >300° C.
IR (KBr, cm-1): 3400, 3250, 1740, 1360, 1165
NMR (DMSO-d6, ppm): 2.14 (3H, s), 4.55 (2H, 7.60-8.56 (6H, m), 10.49 (1H, s), 11.60 (1H, s)
Compounds of Example 6 to 25 prepared in a manner similar to Example 1 are summarized in the following table 3 together with corresponding IR and NMR data and melting points.
TABLE 3
__________________________________________________________________________
##STR4##
Ex. M.P.
No. Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
##STR5## 3250, 1735, 1350, 1160
4.57(2H, s), 7.67˜8.34(5H, m),
8.74(1H, s), 11.60(1H,
259.6˜262.0
7
##STR6## 3250, 1735, 1350, 1165
4.58(2H, s), 7.89˜8.73(6H, m),
11.62(1H, bs) 256.7˜261.0
8
##STR7## 3230, 1730, 1350, 1160
4.57(2H, s), 7.62˜8.80(6H, m),
11.62(1H, bs) 293.0˜299.5
9
##STR8## 3230, 1720, 1350, 1150
4.57(2H, s), 7.69˜8.75(6H, m),
11.61(1H, bs) 238.7˜241.4
10
##STR9## 3160, 1730, 1375, 1170
4.56(2H, s), 7.71˜8.70(6H, m),
11.62(1H, bs) 261.0˜263.9
11
##STR10## 3230, 1730, 1350, 1160
4.56(2H, s), 7.69˜8.82(6H, m),
11.61(1H, bs) 233.7˜235.3
12
##STR11## 3240, 1730, 1360, 1180
4.72(2H, s), 7.74˜8.26(4H, m),
8.54(1H, s), 8.96(1H, s), 11.77(1H,
bs) 298.0˜303.0
13
##STR12## 3220, 1730, 1350, 1160
4.57(2H, s), 7.80˜8.74(6H, m),
11.61(1H, bs) 255.6˜258.6
14
##STR13## 3250, 1735, 1520, 1340, 1150
3.08(3H, s), 4.58(2H,
s), 7.90˜8.73(5H, m), 11.69(1H,
bs) 232.0˜236.5
15
##STR14## 3200, 1725, 1340, 1160
2.70(3H, s), 4.55(2H, s),
7.62˜8.14 (5H, m), 8.75(1H, s),
11.65(1H, bs) 271.4˜277.3
16
##STR15## 3170, 1730, 1530, 1370, 1170
2.52(3H, s), 4.55(2H, s),
7.74˜8.48 (4H, m), 8.85(1H, s),
11.62(1H, bs) 295.0˜296.1
17
##STR16## 3240, 1735, 1350, 1160
2.53(3H, s), 4.56(2H,
s), 7.51˜8.63(6H, m), 11.58(1H,
bs) 212.1˜215.3
18
##STR17## 3180, 1740, 1530, 1370, 1170
4.11(3H, s), 4.54(2H,
s), 7.75˜8.83(5H, m), 11.61(1H,
bs) 285.9˜286.4
19
##STR18## 3170, 1720, 1365, 1180
4.56(2H, s), 7.78˜8.20(6H, m),
11.67(1H, bs) 231.0˜234.0
20
##STR19## 3230, 1730, 1350, 1150
4.50(2H, s), 7.78˜8.39(6H, m),
11.60(1H, bs) 162.6˜166.0
21
##STR20## 3250, 1735, 1365, 1165
4.02(3H, s), 4.06(3H, s), 4.54(2H,
s), 7.72˜8.80(4H, m), 11.65(1H,
bs) 228.0˜230.0
22
##STR21## 3150, 2230, 1735, 1380, 1170
4.57(2H, s), 8.01˜8.91(5H, m),
11.65(1H, bs) 279.0˜285.0
23
##STR22## 3230, 2240, 1740, 1380, 1160
4.58(2H, s), 7.93˜8.49(4H, m),
8.75 (1H, s), 8.84(1H, s), 11.63(1H,
bs) 261.6˜264.6
24
##STR23## 3230, 1740, 1380, 1170
4.54(2H, s), 8.27˜8.87(3H, m),
11.60(1H, bs) >300
25
##STR24## 3240, 1740, 1370, 1170
2.94(6H, s), 4.53(2H,
s), 7.35˜8.59(6H, m), 11.56(1H,
bs) 102.9˜104.5
__________________________________________________________________________
To a solution of benzo[b]thiophen (38.3 g) in anhydrous ether (180 ml) was added dropwise 1.6 M solution of n-butyllithium in hexane (220 ml) under ice-cooling and nitrogen atmosphere. After refluxing for 40 minutes, into the solution was bubbled sulfur dioxide for 2.75 hours with stirring at -30° C. Then the solution was stirred for 1 hour and the formed precipitate was separated by filtration to give lithium benzo[b]thiophen-2-ylsulfinate. Into the suspension of the product in concentrated hydrochloric acid (400 ml) and water (100 ml) was bubbled chlorine gas for 1.5 hours with stirring at -5° C. The resulting solution was poured into ice-water (500 ml) and extracted with dichloromethane (1.51×2) and the organic layer was washed with saturated aqueous NaCl solution. After drying over anhydrous magnesium sulfate, dichloromethane was removed in vacuo, and the residue was purified by silica gel column chromatography to give 40.4 g of the objective compound.
IR (KBr, cm-1): 1495, 1384, 1189, 1168, 1155
NMR (CDCl3, ppm): 7.49-7.68 (2H, m), 7.86-8.03 (2H, m), 8.14 (1H, s)
Starting from benzo[b]thiophen-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 of Example 1.
Melting point: 171.3°-172.4° C.
IR (KBr, cm-1): 3267, 1735, 1352, 1258, 1115, 1115
NMR (DMSO-d6, ppm): 3.73 (2H, d, J=6.0 Hz), 7.39-7.61 (2H, m), 7.77-8.13 (3H, m), 8.51 (1H, d, J=6.0 Hz), 12.68 (1H, bs)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 2 or Example 1.
Melting point: 218.6° C. (decomposition)
IR (KBr, cm-1): 1759, 1374, 1255, 1171, 1157
NMR (DMSO-d6, ppm): 4.74 (2H, s), 7.35-7.69 (2H, m), 8.04-8.21 (2H, m), 8.45 (1H, s), 12.72 (1H, bs)
To a suspension of iodine monochloride (7.12 ml) in 1 N hydrochloric acid (200 ml) were added successively the product obtained in Step 3 (8.50 g) and dichloromethane (200 ml). The mixture was stirred for 20 minutes at room temperature. After adding sodium bicarbonate (6.85 g), the reaction mixture was stirred for 15 minutes and extracted twice with ethyl acetate (11+300 ml). The organic layer was washed with saturated aqueous sodium bisulfite solution and then saturated aqueous NaCl solution, and dried over anhydrous magnesium sulfate. Ethyl acetate was removed in vacuo, the residue was washed with dichloromethane to give 4.83 g of the objective compound.
Melting point: 251.8°-254 2° C.
IR (KBr, cm-1): 3245, 1803, 1740, 1376, 1352, 1167
NMR (DMSO-d6, ppm): 4.48 (2H, s), 7.51-7.63 (2H, m), 8.05-8.20 (2H, m), 8.33 (1H, s), 11.71 (1H, bs)
Starting from benzo[b]furan, the objective compound was obtained in a manner similar to Step 1 of Example 26.
IR (KBr, cm-1): 1533, 1389, 1244, 1193, 1166
NMR (CDCl3, ppm): 7.32-7.82 (5H, m)
Starting from benzo[b]furan-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 of Example 1.
Melting point: 177.0°-178.2° C.
IR (KBr, cm-1): 3289, 1724, 1347, 1162
NMR (DMSO-d6, ppm): 3.77 (2H, d, J=6.3 Hz), 7.35-7.81 (5H, m), 8.72 (1H, t, J=6.3 Hz), 12.69(1H, bs)
To a suspension of the product obtained in Step 2 (37.0 g) and ammonium thiocyanate (24. 3 g) in acetic anhydride (100 ml) was added dropwise anhydrous pyridine (30.5 ml), and the mixture was heated with stirring for 1.5 hours at 70°-80° C. After cooling to room temperature, the resultant solution was poured into ice (800 g), and the formed precipitate was separated by decantation. The precipitate was washed with water and dried to give 18.5 g of the objective compound.
Melting point: 213.0° C. (decomposition)
IR (KBr, cm-1): 3080, 1759, 1386, 1255. 1167 1096
NMR (DMSO-d6, ppm): 4.76 (2H, s), 7.34-8.04 (5H, m), 12.81 (1H, bs)
Starting from the product obtained in Step 3, the objective compound was obtained in a manner similar to Step 4 of Example 26.
Melting point: 255.9°-256.4° C.
IR(KBr, cm-1): 1803, 1735, 1398, 1360, 1166
NMR (DMSO-d6, ppm): 4.49 (2H, s), 7.33-8.08
Compounds of Example 28 to 52 prepared in a manner similar to Example 26 are summarized in the following table 4 together with corresponding IR and NMR data and melting points.
TABLE 4
__________________________________________________________________________
##STR25##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm) (°C.)
__________________________________________________________________________
28
##STR26## 1803, 1755, 1516, 1372, 1350, 1165
4.55(2H, s), 7.86˜9.10(6H, m),
11.62(1H, bs) 284.6 (dec.)
29
##STR27## 1735, 1508, 1382, 1167
4.47(2H, s), 7.40˜8.30(3H, m),
8.30(1H, s), 11.73(1H,
275.2 (dec)
30
##STR28## 1739, 1380, 1192
4.45(2H, s), 7.57˜7.69(1H, m),
8.15˜8.25(2H, m), 8.29(1H, s),
11.70(1H, bs) >300
31
##STR29## 1728, 1381, 1183, 1162
4.64(2H, s), 7.58˜7.81(2H, m),
7.96˜8.06(1H, m),
8.18˜8.29(1H, m), 11.82(1H,
278.3 (dec.)
32
##STR30## 3270, 1741, 1379, 1162
4.51(2H, s), 7.52˜7.67(2H, m),
8.16˜8.23(2H, m), 11.74(1H,
271.1˜272.2
33
##STR31## 3400, 1730, 1663, 1614, 1380, 1169
3.96(2H, s), 7.61˜8.06(4H,
270.2 (dec.)
34
##STR32## 3379, 1616, 1608, 1381, 1233, 1166.
3.98(2H, s), 7.47˜7.90(4H,
290.0 (dec.)
35
##STR33## 1740, 1376, 1166
2.88(3H, s), 4.53(2H, s), 8.10(2H, s),
8.80(1H, s), 11.59(1H,
258.0 (dec.)
36
##STR34## 3328, 1740, 1390, 1159
4.60(2H, s), 7.33˜7.78(5H, m),
11.85(1H, bs) 222.8 (dec.)
37
##STR35## 1741, 1380, 1162
4.54(2H, s), 7.52˜7.63(2H, m),
8.10˜8.29 (2H, m), 8.86(1H, s),
11.58(1H, bs) 218.3˜226.7
38
##STR36## 1739, 1377, 1165
4.49(2H, s), 7.50˜8.28(4H, m),
11.68(1H, bs) 237.8˜243.0
39
##STR37## 1746, 1682, 1363, 1158
2.59(3H, s), 4.07(3H, s), 4.51(2H, s),
7.57˜8.13(3H, m), 11.55(1H,
263.0 (dec.)
40
##STR38## 1735, 1691, 1387, 1173
2.63(3H, s), 4.10(3H, s), 4.54(2H, s),
7.36(1H, d, J=8.6Hz), 8.02(2H, m),
11.56(1H, bs) 242.3˜244.1
41
##STR39## 1803, 1746, 1716, 1377, 1164
4.51(2H, s), 6.64(1H, d, J=9.9Hz),
7.62(1H, d, J=8.9Hz), 8.11˜8.46(3H,
m), 11.60(1H, bs) 262.8˜267.8
42
##STR40## 1741, 1371, 1169
2.87(3H, s), 4.55(2H, s), 7.95˜8.51
(3H, m), 11.59(1H, bs) 245.2˜246.3
43
##STR41## 1741, 1362, 1168
4.55(2H, s), 8.12(2H, s), 8.82(1H, s),
12.67(1H, bs)
44
##STR42## 3098, 1743, 1385, 1364, 1186, 1162, 1067
4.52(2H, s), 7.99˜8.66(3H, m),
9.45(1H, d, J=1.0Hz), 11.59(1H,
203 (dec.)
45
##STR43## 3095, 1741, 1373, 1360, 1177, 1150
4.56(2H, s), 7.51˜8.51(5H, m),
11.59(1H, bs) 238.7˜244.9
46
##STR44## 1729, 1362, 1166
4.54(2H, s), 7.66˜8.59(5H, m),
11.56(1H, bs) 268.4˜271.4
47
##STR45## 3174, 1735, 1390, 1170
4.61(2H, s), 7.57˜7.74(2H, m),
7.95˜8.34(3H, m), 11.55(1H,
242.9˜244.3
48
##STR46## 1800, 1742, 1396, 1162
4.43(2H, s), 6.78(1H, m), 7.45(1H, d,
J=3.6Hz), 8.09(1H, m), 11.72(1H,
243.0˜244.2
49
##STR47## 3227, 1735, 1365, 1183, 1171
4.51(2H, s), 7.55(1H, s), 11.76(1H,
251.2˜251.3
50
##STR48## 1742, 1375, 1174
4.53(2H, s), 7.71(1H, m), 8.40(1H, m),
8.89˜9.14(2H, m), 11.65(1H,
175.5 (dec.)
51 CH.sub.3 1744, 1384, 1359, 1164, 1153
3.35(3H, s), 4.33(2H, s),
196.2˜198.3
11.65(1H, bs)
52
##STR49## 1749, 1727, 1371, 1170
4.55(2H, s), 7.38˜8.16(9H, m),
11.63(1H, bs) 261.0˜261.5
__________________________________________________________________________
Starting from 2,3-diphenyhhiophen, the objective compound was obtained in a manner similar to Step 1 of Example 26.
IR (KBr, cm-1): 1382, 1172, 1038, 698, 583
NMR (CDCl3, ppm): 7.27-7.33 (10H, m), 7.89 (1H, s)
To a suspension of 4,5-diphenyhhiophen-2-ylsulfonyl chloride (36.5 g) and glycine ethyl ester hydrochloride (30.4 g) in dichloromethane (320 ml) was added slowly triethylamine (3.03 mi) under ice-cooling, and the mixture was stirred for 160 minutes at room temperature. Water (200 ml) was added to the resultant solution, and extracted with dichloromethane. The organic layer was washed successively with 1N hydrochloric acid, water and saturated aqueous NaCl solution, and dried over anhydrous magnesium sulfate. Dichloromethane was removed in vacuo, and the residue was reprecipitated from ethyl acetate and hexane to give 41.1 g of the objective compound.
Melting point: 151.2°-152.7° C.
IR (KBr, cm-1): 3266, 1734, 1354, 1231, 1215, 1164, 1127
NMR (DMSO-d6, ppm): 1.12 (3H, t, J=7.1 Hz), 3.88 (2H, d, J=6.3 Hz), 4.04 (2H, q, J=7.1 Hz), 6.84-7.44 (10H, m), 7.67 (1H, s), 8.57 (1H, t, J=6.3 Hz)
A solution of sodium hydroxide (12.4 g) in water (73 ml) was added to a solution of the product obtained in Step 2 (41.4 g) in tetrahydrofuran (730 ml), and the mixture was stirred for 25 minutes at 60° C. After removing the solvent, water (300 ml) was added to the residue, and the resultant solution was acidified with concentrated hydrochloric acid to a pH 1 under ice-cooling. The acidified solution was extracted thrice with ethyl acetate (800 ml), the organic layer was washed with water, then with maturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, the residue was reprecipitated from ethyl acetate and hexane to give 37.6 g of the objective compound.
Melting point: 172.2°-174.4° C.
IR (KBr, cm-1): 3268, 1736, 1353, 1159
NMR (DMSO-d6, ppm): 3.78 (2H, d, J=5.9 Hz), 7.12-7.42 (10H, m), 7.67 (1H, s), 8.39 (1H, t, J=5.9 Hz), 12.78 (1H, bs)
Starting from the product obtained in Step 3, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 213.2°-215.4° C.
IR (KBr, cm-1): 1752, 1446, 1376, 1168, 1083
NMR (DMSO-d6, ppm): 4.77 (2H, s), 7.32-7.46 (10H, m), 8.12 (1H, s), 12.73 (1H, bs)
Starting from the product obtained in Step 4, the objective compound was obtained in a manner similar to Step 4 of Example 26.
Melting point: 242.5°-243.9° C.
IR (KBr, cm-1): 1737, 1386, 1165
NMR (DMSO-d6, ppm): 4.53 (2H, s), 7.32-7.45 (10H, m), 8.00 (1H, s), 11.72 (1H, bs)
Compounds of Example 54 and 55 prepared in a manner similar to Example 53 are summarized in the following table 5 together with corresponding IR and NMR data and melting points.
TABLE 5
__________________________________________________________________________
##STR50##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
54
##STR51## 1721, 1367, 1349, 1172, 1161
0.96˜2.40(10H, m),
3.30˜3.69(1H, m), 4.31(2H, s),
11.61(1H, bs) 154.9˜156.7
55
##STR52## 1735, 1725, 1359, 1163
0.69˜1.98(15H, m),
3.42˜3.59(2H, m), 4.33(2H, s),
11.64(1H, bs) 141.3˜143.2
__________________________________________________________________________
To a solution of 5-nitrobenzo[b]thiophen (60 g) in anhydrous tetrahydrofuran (2 l) was added dropwise a solution of lithium diisopropylamide comprising 1.6M n-butyllithium in hexane (240 ml) and diisopropylamine (57.8 ml) and anhydrous ether (170 ml) with stirring at -70° C. under nitrogen atmosphere. After stirring for 30 minutes into the solution was bubbled sulfur dioxide for 90 minutes with stirring at -70° C. Then the solution was stirred for 1 hour at room temperature and the formed precipitate was separated by filtration to give lithium 5-nitrobenzo[b]-thiophen-2-ylsulfinate. Into the suspension of the product in concentrated hydrochloric acid (500 ml) and water (125 ml) was bubbled chlorine gas for 3 hours with sufficiently stirring at below 0° C. After stirring for 1 hour at room temperature, the resulting suspension was extracted with dichloromethane (400 ml×2) and the organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, dichloromethane was removed in vacuo, and the residue was purified by silica gel column chromatography to give 21 g of the objective compound.
IR (KBr, cm-1): 1602. 1519, 1378, 1340, 1172
NMR (CDCl3, ppm): 8.10 (1H, d, J=8.9 Hz), 8.31 (1H, s), 8.46 (1H, dd, J=8.9, 2.0 Hz), 8.90 (1H, d, J=2.0 Hz)
Starting from 5-nitrobenzo[b]thiophen-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 or Example 1.
Melting point: 187.2°-194.8° C.
IR (KBr, cm-1): 3325, 1734, 1530, 1377, 1351, 1159
NMR (DMSO-d6, ppm): 3.76 (2H, d, J=5.9 Hz), 8.22 (1H, s), 8.32-8.91 (4H, m), 12.72 (1H, bs)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 217.4° C. (decomposition)
IR (KBr, cm-1): 1762, 1521, 1470. 1389, 1347, 1248, 1173, 1087
NMR (DMSO-d6, ppm): 4.73 (2H, s), 8.25-9.09 (4H, m), 12.78 (1H, bs)
A mixture of the product obtained in Step 3 (1.66 g) and 50% (w/v) nitric acid (35 ml) was heated with stirring for 6 hours at 60° C, and the resultant solution was poured into ice-water (150 ml). The formed precipitate was separated by filtration and washed with acetone to give 0.47 g of the objective compound.
Melting point: 282.4° C. (decomposition)
IR (KBr, cm-1): 3100, 1737, 1522, 1385, 1349, 1176
NMR (DMSO-d6, ppm): 4.47 (2H, s), 8.22-9.05 (4H, m), 11.70 (1H, bs)
Starting from benzo[b]thiophen-5-ylcarbonitrile, the objective compound was obtained in a manner similar to Step 1 of Example 56.
IR (KBr, cm-1): 2236, 1500, 1376, 1171, 577
NMR (DMSO-6, ppm): 7.56 (1H, s), 7.70 (1H, dd, J=8.9, 2.0 Hz), 8.15 (1H, d, J=8.9 Hz), 8.37 (1H, d, J=2.0 Hz)
Starting from 5-cyanobenzo[b]thiophen-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 1 of Example 1.
IR (KBr, cm-1): 3289, 2235. 1714, 1350, 1153
NMR (DMSO-d6, ppm): 3.75 (2H, d, J=5.6 Hz), 7.87 (1H, dd, J=8.6, 1.3 Hz), 8.06 (1H, s), 8.34 (1H, d, J=8.6 Hz), 8.56 (1H, d, J=1.3 Hz), 8.70 (1H, t, J=5.6 Hz), 12.69 (1H, bs)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 2 of Example 1.
IR (KBr, cm-1): 2231, 1762, 1451, 1243, 1173, 1077
NMR (DMSO-d6, ppm): 4.73 (2H, s), 7.95 (1H, dd, J=8.6, 1.7 Hz), 8.41 (1H, d, J=8.6 Hz), 8.53 (1H, s), 8.63 (1H, d, J=1.7 Hz), 12.72 (1H, bs)
A mixture of the product obtained in Step 3 (0.39 g) and 50% (w/v) nitric acid (8.2 mi) was heated with stirring for 5 minutes at 80° C., then for 30 minutes at room temperature, and the resultant solution was poured into ice-water (35 ml). The formed precipitate was separated by filtration and washed with acetone (100 ml) to give 0.11 g of the objective compound.
Melting point: 276.3° C. (decomposition)
IR (KBr, cm-1): 3100, 2231, 1740, 1386, 1172
NMR DMSO-d6, ppm) 4.47 (2H, s), 7.95 (1H, dd, J=8.6, 1.7 Hz), 8.41 (1H, s), 8.42 (1H, d, J=8.6 Hz), 8.65 (1H, d, J=1.7 Hz), 11.75(1H, bs)
To the suspension of the product obtained in Step 4 of Example 57 (0.1 g) in water (1.5 ml) was added slowly concentrated sulfuric acid (1.5 ml) and acetic acid (1.5 ml) under ice-cooling, and the mixture was stirred under reflux for 2 hours. After cooling to room temperature, the formed precipitate was separated by filtration and washed with acetone (20 ml). The washings were concentrated in vacuo, and the residue was triturated with ether (2 ml) to give 0.02 g of the objective compound.
Melting point: >300° C.
IR (KBr, cm-1): 1743, 1690, 1380. 1163
NMR (DMSO-d6, ppm): 4.46 (2H, s), 8.07 (1H, dd, J=8.6, 1.7 Hz), 8.28 (1H, d, J=8.6 Hz), 8.48 (1H, s), 8.69(1H, d, J=1.7 Hz)
To a solution of lithium diisopropylamide comprising 1.6M n-butyllithium in hexane (422 ml), diisopropylamine (101 ml) and anhydrous ether (260 ml) was added dropwise, solution of 1-benzenesulfonylindole (150 g) in anhydorous ether (2060 ml) with stirring at 0° C. After stirring for 15 mlnutes at 0° C., the solution was poured into sulfuryl chloride (125 ml) at -50° C. and stirred for 2 hours. The resulting solution was poured into ice-water (2.51) and stirred sufficiently and then the organic layer was extracted. The aqueous layer was extracted with ethyl acetate (2l) and the combined organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ether and ethyl acetate were removed in vacuo and the residue was triturated with ether to give 146 g of the objective compound.
IR (KBr, cm-1): 1513, 1387, 1378, 1245, 1188
NMR (CDCl3, ppm): 7.29-8.36 (10 H, m)
N-(1-benzenesulfonylindol-2-ylsulfonyl)glycine ethyl ester
Starting from 1-benzenesulfonylindol-2-ylsulfonyl chloride, the objective compound was obtained in a manner similar to Step 2 of Example 53.
IR (KBr, cm-1): 3335, 1746, 1346, 1338, 1171
NMR(DMSO-d6, ppm): 1.11 (3H, t, J=7.3 Hz),3.94 (2H, d, J=5.6 Hz), 4.06 (2H, q, J=7.3 Hz), 6.38 (1H, t. J=5.6 Hz), 7.14-8.32 (10H, m)
A solution of sodium hydroxide (1.6 g) in water (7 ml) was added to a solution of the product obtained in Step 2 (4.22 g) in tetrahydrofuran (70 ml) at room temperature, and the mixture was stirred for 5 mlnutes at 65°-75° C. After removing tetrahydofuran in vacuo, a solution of sodium hydroxide (0.4 g) in water (23 ml) was added to the residue, and the mixture was stirred for 5 hours at 65°-75° C. After cooling to room temperature, the resultant solution was washed with ether, acidified with 6N hydrochloric acid to a pH 1 under ice-cooling, and extracted with ethyl acetate (15 ml×3). The organic layer was washed with water and saturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, and the residue was triturated with ethyl acetate and hexane to give 1.66 g of the objective compound.
Melting point: 170.2°-171.9° C.
IR (KBr, cm-1): 3328, 1707, 1340, 1155, 1145
NMR (DMSO-d6, ppm): 3.73 (2H, d, J=6.3 Hz), 6.94-7.70 (5H, m), 8.05 (1H, t, J=6.3 Hz), 11.90 (1H, bs), 12.67 (1H, bs)
Starting from the product obtained in Step 3, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 209.2°-210.4° C.
IR (KBr, cm-1): 3131, 3103, 1755, 1473, 1367, 1249, 1197, 1165, 1147, 1079
NMR (DMSO-d6, ppm): 4.81 (2H, s), 7.08-7.78 (5H, m), 12.33 (1H, bs), 12.66 (1H, bs)
Starting from the product obtained in Step 4, the objective compound was obtained in a manner similar to Step 4 of Example 26.
Melting point: 287.1° C. (decomposition)
IR (KBr, cm-1): 3290, 1787, 1725, 1389, 1365, 1156
NMR (DMSO6, ppm): 4.67 (2H, s), 7.29-7.58 (5H, m), 11.67 (1H, bs), 12.63 (1H, bs)
To a solution of methyl 6-aminochromon-2-carboxylate (20 g) in water (132 ml) was added concentrated sulfuric acid (26.4 m') and then sodium nitrite (9.0 g) at 0° C. After stirring for 30 mlnutes, to the solution was added sulfur dioxide (19.7 ml), acetic acid (112 ml), concentrated hydrochloric acid (26 ml) and copper (II) chloride dihydrate (11.2 g) and then the mixture was stirred for 15 mlnutes. The formed precipitate was separated by filtration and dissolved in dichloromethane (600 ml) and the resulting solution was washed with saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, dichloromethane was removed in vacuo to give 22 g of the objective compound.
IR (KBr, cm-1): 1744, 1661, 1381, 1287, 1174. 600
NMR (DMSO-d6, ppm): 6.96 (1H, s), 7.70 (1H, d, J=8.6 Hz). 8.04 (1H, dd, J=8.6, 2.0 Hz), 8.25 (1H, d, J=2.0 Hz)
To a suspension of 2-methoxycarbonylchromon-6-ylsulfonyl chloride (20.0 g) in acetone (600 ml) was added slowly a solution of glycine (6.15 g), sodium hydroxide (3.28 g) and sodium bicarbonate (6.11 g) in water (300 ml), and the mixture was stirred for 85 mlnutes at room temperature. After adjusting a pH of the resultant solution to ca. 6 with 6 N hydochloric acid, acetone was removed in vacuo, and insoluble matters were filtered off. The filtrate was acidified with 2 N hydrochloric acid to a pH 1 under ice-cooling. The acidified solution was extracted with ethyl acetate (350 ml×3), the organic layer was washed with water, then saturated aqueous NaCl solution. and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, the residue was purified by silica-gel column chromatography to give 5.45 g of the objective compound.
Melting point: 210.6°-212.8° C.
IR (KBr, cm-1): 3327, 1746, 1716, 1659, 1288, 1266, 1165
NMR (DMSO-d6, ppm): 3.67 (2H, d, J=5.9 Hz), 3.96 (3H, s), 7.04 (1H, s), 7.89-8.42 (4H, m)
Starting from the product obtained in Step 2, the objective compound was obtained in a manner similar to Step 2 of Example 1.
Melting point: 217.4° C. (decomposition)
IR (KBr, cm-1): 1746. 1660, 1443, 1374, 1282, 1260, 1174
NMR (DMSO-d6, ppm): 3.96 (3H, s), 4.84 (2H, s), 7.07 (1H, s), 7.9-8.71 (3H, m), 12.68 (1H, bs)
Starting from the product obtained in Step 3, the objective compound was obtained in a manner similar to Step 4 of Example 26.
Melting point: >300° C.
IR (KBr, cm-1): 1751, 1741, 1664, 1617, 1375. 1177,
NMR (DMSO-d6, ppm): 3.96 (3H, s), 4.52 (2H, s) 7.07 (1H, s), 7.98-8.64 (3H, m)
A solution of the product obtained in Step 4 (2.27 g) in a saturated aqueous sodium bicarbonate solution (22.7 ml) was stirred for 2 hours at 40° C. The resultant solution was washed with ethyl acetate and acidified with 2 N hydrochloric acid to a pH 1 under ice-cooling, and the formed precipitate was separated by filtration to give 0.82 g of the objective compound.
Melting point: 279.3° C. (decomposition)
IR, (KBr, cm-1): 3220, 1751, 1663, 1376, 1172
NMR (DMSO-d6, ppm): 4.54 (2H, s), 7.02 (1H, s), 7.95-8.61 (3H, m), 11.63 (1H, bs)
To a solution of 2-benzothiazolthlol (250 g) in N,N-dimethylformamide (1l) was added triethylamine (208 ml) under ice-cooling and dropwise a solution of benzyl bromide (178 ml) in N,N-dimethylformamide (300 ml) and the mixture was stirred for 40 minutes. The resulting solution was poured into water (101) and the formed precipitate was separated by filtration and dissolved in dichloromethane (3 l). After drying over anhydorpus magnesium sulfate, dichloromethane was removed in vacuo to give 378 g of the objective compound.
Into a mixture of 2-benzylthiobenzothiazole (100 g) and acetic acid (500 ml) in water (500 ml) was bubbled chlorine gas for 1.5 hours with stirring at -1:5° C. The resulting solution was poured into icewater (1.5 l), the formed precipitate was separated by filtration to give 90.9 g of the objective compound.
To a suspension of glycinamide hydrochloride (43 g) in dioxane (1l) was added benzothiazol-2-ylsulfonyl chloride (90.9 g) under ice-cooling, and a pH of the mixture was adjusted to 8 with saturated aqueous sodium carbonate solution. After stirring for 1.5 hours, the resultant solution was concentrated in vacuo. Water (1.5l) was added to the residue, and the solution was acidified with concentrated hydrochloric acid to pH 2. The formed precipitate was separated by filtration to give 59.8 g of the objective compound.
Melting point: 179.7°-181.8° C.
IR (KBr, cm-1): 3426, 1682. 1345, 1165
NMR (DMSO-d6, ppm): 3.73 (2H, s), 7.08 (1H, bs), 7.50 (1H, bs). 7.52-8.29 (4H, m), 8.80 (1H, bs)
To a solution of the product obtained in Step 3 (102.3 g) in N,N-dimethylformamide 0.2l) was added slowly 60% sodium hydride (16.7 g) under ice-cooling, and the mixture was stirred for 1 hour at room temperature. Methyl chlorocarbonate (35.8 g) was added to the above-mentioned mixture followed by stirring for 1 hour at room temperature. After removing the solvent, water (3.5 l) was added to the residue, and the formed precipitate was separated by filtration to give 60.5 g of the objective compound.
Melting point: 153.1° C. (decomposition)
IR (KBr, cm-1): 3459, 3346, 1737, 1689, 1386, 1343, 1250, 1171
NMR (DMSO-d6, ppm): 3.10 (3H, s), 4.51 (2H, s), 7.30 (1H, bs), 7.60-7.76 (3H, m), 8.20-8.39 (2H, m)
To a solution of the product obtained in Step 4 (20.0 g) in N,N-dimethylformamide (200 ml) added slowly 60% sodium hydride (2.67 g), and the mixture was stirred for 13.5 hours at 70° C. After removing the solvent, water (1) was added to the residue, and the solution was extracted with ethyl acetate (1.5 l). The organic layer was washed with saturated aqueous NaCl solution, and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo, and the residue was washed with acetone-chloroform (100 ml+200 ml) to give 2.12 g of the objective compound.
Melting point: 260.4°-261 9° C.
IR (KBr, cm-1): 3200, 3105, 1739, 1393, 1355, 1173
NMR (DMSO-d6, ppm): 4.55 (2H, s), 7.61-7.81 (2H, m), 8.18-8.40 (2H, m). 11.88 (1H, bs)
To a solution ot benzo[c]thiophen (5.5 g) in anhydrous ether (50 ml) was added 1.6 M solution of n-butyllithium in hexane (52.2 ml) at -20° C. under nitrogen atmosphere. After stirring for 1 hour, into the solution was bubbled sulfur dioxide for 1 hour with stirring at -20° C. Ether was removed in vacuo and the residue was suspended in isopropanol (200 ml) and water (200 ml). To the suspension was added N-chlorosuccinimide (6.5 g) at 0° C. After stirring for 30 minutes at 0° C., N-chlorosuccinimide (1.63 g) was added and the mixture was stirred for additional 1 hour. The resulting solution was extracted with dichloromethane (1 l×2) and the organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, dichloromcthane was removed in vacuo under cooling. Using this residue and glycinamide hydrochloride, the objective compound was obtained in a manner similar to Step 3 of Example 50.
NMR (DMSO-d6, ppm): 3.40 (2H, d, J=6.9 Hz), 7.06-8.22 (5H, m), 8.49 (1H, s)
To a solution of the product obtained in Step 1 (0.45 g) in N,N-dimethylformamide (5 ml) was added slowly (60% sodium hydride (75 mg) under ice-oooling, and the mixture was stirred for 30 minutes at room temperature. Methyl chloroformate (0.14 ml) was added to the above-mentioned mixture followed by stirring for 20 minutes at room temperature. 60% sodium hydride (75 mg) was added to the solution, and the mixture was stirred for 1.5 hours at room temperature, then 15 minutes at 70° C. After cooling to room temperature, water (20 ml) was added to the resultant mixture and this aqueous solution was extracted with ethyl acetate (20 ml×3). The organic layer was washed with water, then saturated aqueous NaCl solution. After drying over anhydrous magnesium sulfate, ethyl acetate was removed in vacuo and the residue was purified by silica-gel columun chromatography to give 0.18 g of the objective compound.
NMR (CDCl3, ppm): 3.74 (3H, s), 4.24 (2H, d, J=5.3 Hz), 5.92 (1H, t, J=5.3 Hz), 7.17-8.31 (6H, m)
To a solution of the product obtained in Step 2 (0.18 g) in N,N-dimethylformamide (3 ml) added slowly 60% sodium hydride (48 mg), and the mixture was stirred for 2.5 hours at 70° C. After removing the solvent, ice water (20 ml) was added to the residue, and pH of the solution was adjusted to 4 with 1 N hydrochloric acid. The resultant solution was extracted with ethyl acetate (20 ml×3), and the organic layer was washed with saturated aqueous NaCl solution, and dried over anhydrous magnesium sulfate. Ethyl acetate was removed in vacuo, and the residue was triturated with dichloromethane to give 0.03 g of the objective compound.
Melting point: 223.6°-226.9° C.
IR (KBr, cm-1): 1736, 1378, 1185, 1162, 1152
NMR (DMSO-d6, ppm): 4.51 (2H, s), 7.20-8.16 (4H, m)8.82 (1H, s), 11.54 (1H, bs)
Intermediate compounds of Example 6 to 25, 28 to 52, 54 and 55 are summarized to the following table 6 and 7 together with corresponding IR and NMR data and melting points.
TABLE 6
__________________________________________________________________________
QSO.sub.2 NHCH.sub.2 CO.sub.2 H
Ex. No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
M.P. (°C.)
__________________________________________________________________________
##STR53## 3345, 1710, 1315, 1140
3.69(2H, d), 7.61˜8.37(6H, m),
8.49(1H, s) 174.5˜ 182.1
7
##STR54## 3.70(2H, d, J=5.9Hz), 7.72˜8.50(7H,
m) 185.2˜ 186.4
8
##STR55## 3.44(2H, s), 7.52˜8.60(7H,
>300
9
##STR56## 3350, 1715, 1320, 1145
3.55(2H, d, J=5.8Hz), 7.51˜8.30(6H,
m), 8.48(1H, s)
158.8˜ 165.7
10
##STR57## 3.73(2H, s), 7.51˜8.53(7H,
247.8˜ 254.7
11
##STR58## 3.69(2H, d, J=6.0Hz), 7.58˜8.71(7H,
m) 157.8˜ 162.1
12
##STR59## 3345, 1715 1330, 1165
3.78(2H, d, J=5.9Hz), 7.61˜8.22(5H,
m), 8.42(1H, s), 8.64(1H,
210.0˜ 214.4
13
##STR60## 3350, 1715, 1320, 1145
3.48(2H, s), 7.52˜8.48(7H,
257.2˜ 265.7
14
##STR61## 2.98(3H, s), 3.62(2H, d, J=5.9Hz),
7.52˜8.35(7H, m)
179.0˜ 182.7
15
##STR62## 2.79(3H, s), 3.73(2H, d, J=6.1Hz),
7.43˜8.35(6H, m), 8.53(1H,
155.5˜ 160.5
16
##STR63## 2.49(3H, s), 3.40(2H, s), 7.35˜8.39
(7H, m) 225.7˜ 230.6
17
##STR64## 2.49(3H, s), 3.65(2H, s), 7.35˜8.45
(7H, m) 147.4˜ 152.0
18
##STR65## 3340, 1710, 1325, 1155
3.62(2H, d, J=6.0Hz), 3.91(3H, s),
7.19˜8.15(6H, m), 8.31(1H,
161.4˜ 163.6
19
##STR66## 3.78(2H, d, J=5.9Hz), 7.67˜8.45(7H,
m) 163.5˜ 168.5
20
##STR67## 3.62(2H, s), 7.05˜8.50(7H,
109.0˜ 109.5
21
##STR68## 3.55(2H, s), 3.93(6H, s), 7.35˜7.98
(5H, m), 8.24(1H, s)
212.6˜ 217.1
22
##STR69## 3280, 2230, 1760, 1155
3.71(2H, d, J=6.0Hz), 7.87˜8.65(6H,
m) 231.9˜ 234.9
23
##STR70## 3260, 2240, 1740, 1155
3.69(2H, d, J=6.0Hz), 7.82˜8.73(7H,
m) 186.2˜ 192.0
24
##STR71## 3.72(2H, d, J=5.7Hz), 8.09˜8.68(4H,
m) 258.8˜ 261.5
25
##STR72## 3.06(6H, s), 3.55(2H, d, J=6.0Hz),
6.91˜8.21(7H, m)
148.0˜ 152.0
28
##STR73## 3348, 1710, 1518, 1334, 1142
3.68(2H, d, J=6.3Hz), 7.78˜8.89(7H,
m), 12.63(1H, bs)
224.9˜ 227.7
29
##STR74## 3290, 1709, 1342, 1156
3.73(2H, d, J=5.9Hz), 7.31˜8.22(4H,
m), 8.59(1H, t, J=5.9Hz), 12.72(1H,
162.7˜ 164.2
30
##STR75## 3295, 1709, 1343, 1156
3.73(2H, d, J=5.9Hz), 7.49˜8.17(4H,
m), 8.59(1H, t, J=5.9Hz), 12.54(1H,
186.9˜ 189.1
31
##STR76## 3337, 1716, 1342, 1257, 1162
3.83(2H, d, J=6.3Hz), 7.52˜8.24(4H,
m), 8.87(1H, t, J=6.3Hz), 12.63(1H,
156.6˜ 161.0
32
##STR77## 3255, 1710, 1356, 1248, 1160
3.78(2H, d, J=5.9Hz), 7.44˜8.13(4H,
m), 8.66(1H, t, J=5.9Hz), 12.68(1H,
197.0˜ 199.2
33
##STR78## 3334, 1717, 1437, 1352, 1241, 1152
3.78(2H, s), 7.49(1H, s), 7.68(2H, s),
8.00(1H, s), 8.83(1H, bs)
192.4˜ 194.1
34
##STR79## 3377, 1718, 1358, 1247, 1157
3.76(2H, s), 7.44˜7.89(4H,
191.5˜ 193.8
35
##STR80## 3290, 1720, 1340, 1170
2.86(3H, s), 3.63(2H, d, J=6.3Hz),
7.79˜8.54(4H, m), 12.48(1H,
237.7 (dec.)
36
##STR81## 3068, 1718, 1617, 1349, 1155
3.78(2H, s), 7.25˜7.70(4H,
133.5˜ 135.9
37
##STR82## 3318, 1724, 1339, 1241, 1152
3.64(2H, d, J=5.9Hz), 7.36˜7.60(2H,
m), 7.97˜8.45(4H, m)
38
##STR83## 3094, 1721, 1358, 1164
3.82(2H, s), 7.43˜8.17(4H, m),
9.09(1H, bs), 12.51(1H,
212.5˜ 214.4
39
##STR84## 3290, 1733, 1655, 1331, 1158
2.58(3H, s), 3.61(2H, d, J=5.9Hz),
4.03(3H, s), 7.49˜8.17(4H, m),
12.50(1H, bs)
215.0˜ 217.6
41
##STR85## 3265, 1748, 1711, 1316, 1205, 1154
3.65(2H, d, J=5.9Hz), 6.62(1H, d,
J=9.9Hz), 7.57(1H, d, J=8.6Hz), 7.92.abou
t.8.25(4H, m), 12.69(1H,
235.0 (dec)
42
##STR86## 3302, 1727, 1330, 1216, 1154
2.85(3H, s), 3.63(2H, d, J=5.9Hz),
7.73˜8.29(4H, m)
257.2 (dec.)
43
##STR87## 3213, 1718, 1317, 1255, 1164, 1153
3.64(2H, d, J=5.6Hz), 7.78˜8.38(4H,
m) 243.5˜ 245.3
44
##STR88## 3271, 1742, 1316, 1149
3.64(2H, d, J=6.3Hz), 7.90˜8.63(4H,
m), 9.38(1H, s), 12.57(1H,
165.3˜ 168.5
45
##STR89## 3097, 1741, 1316, 1209, 1148
3.57(2H, d, J=5.9(Hz), 7.39˜8.33(6H
, m)
46
##STR90## 3186, 1765, 1751, 1732, 1335, 1145
3.60(2H, d, J=6.3Hz), 7.61˜8.35(6H,
m), 12.58(1H, bs)
47
##STR91## 3282, 1727, 1309, 1161, 1137
3.65(2H, d, J=5.9Hz), 7.47˜8.18(5H,
m), 8.33(1H, t, J=5.9Hz), 12.64(1H, bs)
48
##STR92## 3307, 1725, 1340, 1329, 1157
3.66(2H, d, J=6.3Hz), 6.58˜7.90(3H,
m), 8.38(1H, t, J=6.3(Hz), 12.63(1H,
bs)
49
##STR93## 3358, 1728, 1348, 1236, 1166
3.76(2H, d, J=5.9Hz), 7.28(1H, s),
8.45(1H, t, J=5.9Hz), 12.76(1H, bs)
50
##STR94## 3236, 1701, 1341, 1174
3.70(2H, d, J=5.9Hz), 7.54˜8.24(2H,
m), 8.33(1H, t, J=5.9Hz), 8.76˜8.9
6(2H, m), 12.70(1H, bs)
220.4˜ 223.8
51 CH.sub.3 3258, 1711,
2.92(3H, s),
168.0˜
1320, 1247,
3.72(2H, d, J=5.9Hz),
171.0
1148 7.39(1H, t, J=5.9Hz),
12.71(1H, bs)
52
##STR95## 3348, 1714, 1323, 1152
3.62(2H, d, J=6.3Hz), 7.44˜7.87(9H,
m), 8.06(1H, t, J=6.3Hz)
54
##STR96## 3308, 1714, 1319, 1147, 1126
1.18˜2.06(10H, m), 2.64˜3.19(
1H, m), 3.69(2H, d, J=6.0Hz), 7.33(1H,
t, J=6.0Hz) 96.0˜ 100.9
55
##STR97## 3314, 3256, 2921, 1716, 1313, 1141
##STR98##
__________________________________________________________________________
TABLE 7
__________________________________________________________________________
##STR99##
Ex. No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
H.P. (°C.)
__________________________________________________________________________
##STR100## 3130, 1785, 1760, 1165
4.90(2H, s), 7.69˜8.45(5H, m),
8.88(1H, s) 212.9˜ 222.8
7
##STR101## 4.88(2H, s), 7.74˜8.83(6H,
250.1 (dec.)
8
##STR102## 4.89(2H, s), 7.59˜8.43(5H, m),
8.70˜8.96(1H, m)
231.4 (dec.)
9
##STR103## 3150, 1795, 1770, 1170
4.93(2H, s), 7.61˜8.35(5H, m),
8.89(1H, s) 211.4˜ 221.9
10
##STR104## 4.88(2H, s), 7.68˜8.39(5H, m),
8.80(1H, s) 227.8 (dec.)
11
##STR105## 4.89(2H, s), 7.60˜8.29(5H, m),
8.69˜8.87(1H, m)
190.5 (dec.)
12
##STR106## 3270, 1795, 1770, 1170
4.94(2H, s), 7.65˜8.51(5H, m),
8.99(1H, s) 248.5˜ 255.7
13
##STR107## 3120, 1785, 1755, 1165
4.85(2H, s), 7.70˜8.40(5H, m),
8.67˜8.84(1H, m)
198.5˜ 209.5
14
##STR108## 2.97(3H, s), 4.86(2H, s), 7.55˜8.47
(6H, m) 243.9 (dec.)
15
##STR109## 2.64(3H, s), 4.80(2H, s), 7.47˜8.26
(5H, m), 8.81(1H, s)
242.0˜ 244.7
16
##STR110## 2.53(3H, s), 4.91(2H, s), 7.45˜
8.68(5H, m), 8.70(1H, s)
234.8˜ 237.6
17
##STR111## 2.52(3H, s), 4.71(2H, s), 7.29˜8.03
(5H, m), 8.58˜8.69(1H,
232.7˜ 238.2
18
##STR112## 3250, 1790, 1755, 1165
3.94(3H, s), 4.85(2H, s), 7.23˜7.51
(2H, m), 7.87˜8.17(3H, m),
8.67(1H, s) 236.4 (dec.)
19
##STR113## 4.82(2H, s), 7.67˜8.33(6H,
248.0 (dec.)
20
##STR114## 4.86(2H, s), 7.23˜8.61(6H,
177.1˜ 184.7
21
##STR115## 3.95(6H, s), 4.86(2H, s), 7.45˜7.97
(4H, m), 8.45˜8.59(1H,
260.7 (dec.)
22
##STR116## 2230, 1760, 1350, 1170
4.88(2H, s), 7.88˜8.55(4H, m),
8.73˜9.00(1H, m)
223.9 (dec.)
23
##STR117## 2225, 1760, 1350, 1170
4.88(2H, s), 7.81˜8.46(4H, m),
8.64˜8.92(2H, m), 12.60(1H,
131.0˜ 135.8
24
##STR118## 4.86(2H, s), 8.46˜8.99(3H, m),
12.60(1H, bs)
270.0 (dec.)
25
##STR119## 3.10(6H, s), 4.82(2H, s), 6.93˜8.03
(5H, m), 8.47(1H, s)
256.4 (dec.)
28
##STR120## 1793, 1764, 1527, 1345 1172
4.85(2H, s), 7.80˜9.24(6H, m),
12.67(1H, bs)
229.6 (dec.)
29
##STR121## 1757, 1391, 1253, 1176
4.74(2H, s), 7.41˜8.50(4H, m),
12.76(1H, bs)
240.4˜ 242.5
30
##STR122## 1761, 1468, 1385, 1249, 1170
4.73(2H, s), 7.50˜8.46(4H, m),
12.77(1H, bs)
208.3 (dec.)
31
##STR123## 1784, 1756, 1462, 1374, 1245, 1173
4.92(2H, s), 7.50˜8.34(4H, m),
12.95(1H, bs)
275.3 (dec.)
32
##STR124## 1746, 1467, 1382, 1257, 1171
4.79(2H, s), 7.53˜8.40(4H, m),
12.76(1H, bs)
221.2˜ 224.6
33
##STR125## 1751, 1436, 1392, 1237, 1165
4.74(2H, s), 7.65˜8.10(4H, m),
12.72(1H, bs)
186.7˜ 187.7
34
##STR126## 1750, 1458, 1394, 1164
4.74(2H, s), 7.50˜8.07(4H, m),
12.83(1H, bs)
213.9 (dec.)
35
##STR127## 1748, 1378, 1245, 1175
2.88(3H, s), 4.83(2H, s), 8.13(2H, s),
8.87(1H, s), 12.62(1H,
240.4 (dec.)
36
##STR128## 1785, 1758, 1449, 1388, 1255, 1185, 1160
4.84(2H, s), 7.26˜7.86(4H, m),
12.94(1H, bs)
37
##STR129## 3111, 1793, 1762, 1463, 1374, 1174
4.87(2H, s); 7.47˜7.68(2H, m),
8.04˜8.28(2H, m), 9.01(1H, s),
12.64(1H, bs)
38
##STR130## 1757, 1386, 1167
4.83(2H, s), 7.50˜8.34(4H, m),
12.77(1H, bs)
203.1 (dec.)
39
##STR131## 1764, 1680, 1475, 1361, 1319, 1162
2.59(3H, s), 4.08(3H, s), 4.77(2H, s),
7.50˜8.28(3H, m), 12.51(1H,
244.0 (dec.)
40
##STR132## 1746, 1671, 1362, 1305, 1186, 1167
2.63(3H, s), 4.10(3H, s), 4.85(2H, s),
7.32(1H, d, J=8.9Hz), 7.95(1H, s),
8.14(1H, d, J=8.9Hz), 12.54(1H, bs)
41
##STR133## 1745, 1467, 1385, 1360, 1170
4.81(2H, s), 6.65(1H, d, J=9.6Hz),
7.62(1H, d, J=8.9Hz), 8.04˜8.58(3H,
m), 12.66(1H, bs)
230.2 (dec.)
42
##STR134## 1762, 1613, 1370, 1241, 1174
2.87(3H, s), 4.85(2H, s), 7.92˜8.64
(3H, m), 12.61(1H, bs)
226.0 (dec.)
43
##STR135## 1755, 1459, 1380, 1169
2.96(3H, s), 4.89(2H, s), 8.41(2H, s),
9.06(1H, s), 12.60(1H,
222.7 (dec.)
44
##STR136## 1759, 1459, 1370, 1243, 1189, 1162
4.83(2H, s), 7.99˜8.75(3H, m),
9.46(1H, s), 12.64(1H,
264.0 (dec.)
45
##STR137## 1745, 1476, 1362, 1267, 1199, 1170
4.90(2H, s), 7.46˜8.55(5H, m),
12.63(1H, bs)
46
##STR138## 1755, 1474, 1364, 1256, 1200, 1169
4.84(2H, s), 7.50˜8.73(5H, m),
12.58(1H, bs)
47
##STR139## 1743, 1459, 1390, 1346, 1172
4.91(2H, s), 7.55˜8.31(5H, m),
12.71(1H, bs)
48
##STR140## 1753, 1431, 1381, 1191, 1166
##STR141##
49
##STR142## 1795, 1758, 1452, 1432, 1374, 1177
4.77(2H, s), 7.65(1H, s), 12.85(1H, bs)
50
##STR143## 1788, 1755, 1378, 1263, 1173
4.82(2H, s), 7.62˜9.22(4H, m),
12.69(1H, bs)
221.0 (dec.)
51 CH.sub.3 1745, 1470,
3.57(3H, s),
213.4˜
1424, 1361,
4.52(2H, s),
216.0
1165 12.70(1H, bs)
52
##STR144## 1743, 1456, 1374, 1171
4.84(2H, s), 7.47˜8.23(9H, m),
12.65(1H, bs)
54
##STR145## 1791, 1757, 1735, 1453, 1353, 1236, 1169
1.24˜2.23(10H, m), 3.90˜4.32(
1H, m), 4.50(2H, s), 12.70(1H, bs)
55
##STR146## 1748, 1735, 1454, 1363, 1235,
##STR147##
__________________________________________________________________________
Now, typical but non-limiting examples of formulations of the compound of this invention will be shown below.
Compound 13, 300 g of weight, 685 g of lactose and 15 g of magnesium stearate were weighed and mixed until the mixture became homogeneous. The mixture was then filled in No. 1 hard gelatin capsule at 200 mg each to obtain capsule preparation.
Compound 15, 300 g of weight, 550 g of lactose, 120 g of potato starch. 15 g of polyvinyl alcohol and 15 g of magnesium stearate were weighed. The weighed amount of compound 15, lactose and potato starch were mixed until accomplishing homogeneity. Then aqueous solution of polyvinylalcohol was added to the mixture and granulated by wet process. The granules were then dried, mixed with magnesium stearate and pressed into tablets, each weighing 200 mg.
Compound 8, 200 g of weight, 790 g of lactose and 10 g of magnesium stearate were weighed and mixed until the mixture became homogeneous to obtain 20% powder preparation.
Compound 16, 300 g of weight, 685 g of lactose and 15 g of magnesium stearate were weighed and mixed until the mixture became homogeneous. The mixture was then filled in No. 1 hard gelatin capsule at 200 mg each to obtain capsule preparation.
Compound 19, 300 g of weight, 550 g of lactose, 120 g of potato starch, 15 g of polyvinyl alcohol and 15 g of magnesium stearate were weighed. The weighed amount of compound 19, lactose and potato starch were mixed until accomplishing homogeneity. Then aqueous solution of polyvinylalcohol was added to the mixture and granulated by wet process. The granules were then dried, mixed with magnesium stearate and pressed into tablets, each weighing 200 mg.
Compounds of Example 63 to 77 prepared in a manner similar to Example 26 are summarized in the following table 8 together with corresponding IR and NMR data and melting points.
TABLE 8
__________________________________________________________________________
##STR148##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
63
##STR149## 1800, 1750, 1739, 1381, 1160
4.46(2H, s), 7.57(1H, dd, J=8.6, 1.7Hz),
8.11(1H, d, J=8.6Hz), 8.33(2H,
249.1˜ 251.3
64
##STR150## 3096, 1786, 1734, 1376, 1166
4.48(2H, s), 7.50˜7.81(1H, m),
8.11(1H, dd, J=6.6, 1.3Hz), 8.44(1H, s),
11.74(1H, bs)
285.0 (dec.)
65
##STR151## 3210, 1809, 1728, 1392 1160
1.46(6H, d, J=7.3Hz), 3.96˜4.28(1H,
m), 4.52(2H, s), 7.48˜7.67(2H, m),
8.07˜8.32(2H, m), 11.76(1H,
174.1˜ 176.6
66
##STR152## 1733, 1379, 1180
4.53(2H, s), 7.66˜8.38(4H, m),
11.95(1H, bs)
243.2 (dec.)
67
##STR153## 3160, 1805, 1725, 1379, 1183
4.70(2H, s), 7.57˜8.28(4H, m),
11.86(1H, bs)
288.0˜ 289.5
68
##STR154## 1804, 1744, 1378, 1178
##STR155## 196.0˜ 197.5
69
##STR156## 3300, 1779, 1729, 1382, 1173, 1167
4.44(2H, s), 7.95(1H, s), 11.75(1H,
283.2 (dec.)
70
##STR157## 3270, 1807, 1742, 1389, 1169
4.45(2H, s), 7.72(1H, d, J=1.6Hz), 7.96(1H,
d, J=1.0Hz), 8.07(1H, dd, J=1.6, 1.0Hz),
11.78(1H, bs)
290.8 (dec.)
71
##STR158## 3220, 1800, 1783, 1397, 1176, 1154
4.52(2H, s), 7.43˜7.91(4H,
265.7˜ 267.9
72
##STR159## 3080, 1805, 1725, 1378, 1187, 1177
4.62(2H, s), 8.40(1H, s), 11.84(1H,
278.0 (dec.)
73
##STR160## 3209, 3177, 1812, 1726, 1490, 1379, 1305, 1176,
4.69(2H, s), 7.51˜7.90(3H, m),
11.90(1H, bs)
286.0 (dec.)
74
##STR161## 3210, 1806, 1735, 1364, 1158.
1.62˜1.92(4H, m), 2.46˜2.91(4H,
m), 4.40(2H, s), 7.60(1H, s), 11.61(1H,
248.3˜ 249.5
75
##STR162## 1810, 1793, 1396, 1177
4.34(2H, s), 7.43˜7.88(9H, rc),
11.76(1H, bs)
220.4 (dec.)
76
##STR163## 3230, 1742, 1389, 1183
4.47(2H, s), 7.53˜8.13(4H, m),
11.72(1H, bs)
256.0˜ 258.0
77
##STR164## 3103, 1805, 1787, 1729, 1534, 1426, 1383, 1366,
4.41(2H, s), 7.21(1H, d, J=5.6Hz), 8.12(1H,
dd, J=5.6, 4.3Hz), 11.73(1H,
238.2˜ 240.9
__________________________________________________________________________
Compounds of Example 78 to 81 prepared in a manner similar to Example 53 are summarized in the following table 9 together with corresponding IR and NMR data and melting points.
TABLE 9
__________________________________________________________________________
##STR165##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
78
##STR166## 3170, 1787, 1732, 1365, 1171
4.61(2H, s), 7.50˜7.61(2H,
m), 8.04˜8.26(2H, m), 11.72(1H,
215.0˜ 219.0
79
##STR167## 3214, 1778, 1725, 1528, 1439, 1346
4.53(2H, s), 7.49˜7.68(2H,
m), 8.03˜8.17(2H, m), 11.87(1H,
221.1˜ 223.2
80
##STR168## 1810, 1742, 1391, 1165, 1139
4.48(2H, s), 7.28˜7.89(4H, m), 11.61(1H,
bs) 277.0 (dec.)
81
##STR169## 3190, 3040, 1795, 1750, 1372, 1170
2.19(3H, s), 2.54(3H, s), 4.41(2H, s), 11.61(1H,
bs), 12.73(1H, bs)
>300
__________________________________________________________________________
Compounds of Example 82 and 83 prepared in a manner similar to Example 61 are summarized in the following table 10 together with corresponding IR and NMR data and melting points.
TABLE 10
__________________________________________________________________________
##STR170##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
82
##STR171## 3200, 1801, 1724, 1374, 1180
2.47(3H, s), 4.77(2H, s), 7.60˜7.76(2H,
m), 8.09˜8.25(2H, m), 11.83(1H,
213.2˜ 222.0
83
##STR172## 3240, 1990, 1728, 1371, 1163
4.18(3H, s), 4.55(2H, s), 7.55˜7.66(2H,
m), 8.06˜8.14(2H, m), 11.70(1H,
239.7˜ 241.3
__________________________________________________________________________
A mixture of the product obtained in Step 4 of Example 68 (0.85 g) and 60% (w/v) nitric acid (9 ml) was heated with stirring for 140 minutes at 70° C. After cooling to room temperature, the formed precipitate was separated by filtration and washed with ether to give 0.21 g of the objective compound.
Melting point: 224.4° C. (decomposition)
IR (KBr cm-1): 3220, 1800, 1736, 1718, 1374, 1170
NMR (DMSO-d6, ppm): 4.32 (2H, s), 4.47 (2H, s), 7.55-7.65 (2H, m), 7.99-8.19 (2H, m), 11.71 (1H, bs)
To a suspension of the product obtained in Example 82 (0.65 g) in dichloromethanc (26 ml) was added m-chloroperbenzoic acid (0.41 g) and the mixture was stirred for 1.5 hours at room temperature. The resulting solution was concentrated in vacuo and the residue was washed with ether (30 ml). The residue was purified by silica gel column chromatography to give 0.48 g of the objective compound.
Melting point: 215.0°-221.0° C.
IR (KBr, cm-1): 1792, 1743, 1379, 1180
NMR (DMSO-d6, ppm): 3.10 (3H, s), 4.57 (2H, S), 7.51-8.89 (4H, m), 11.81 (1H, bs)
To a suspension of the product obtained in Example 82 (0.65 g) in ethyl acetate (26 ml) was added m-chloroperbenzoic acid (0.82 g) and the mixture was stirred under reflux for 1.5 hours. Additional m-chloroperbenzoic acid (0.16 g) was added and the mixture was stirred under reflux for more 1.5 hours. The resulting solution was concentrated in vacuo and the residue was washed with successive methanol and ether to give 0.40 g of the objective compound.
Melting point: 224.0°-245.0° C.
IR (KBr, cm-1): 1771. 1372, 1324, 1179
NMR (DMSO-d6, ppm): 3.47 (3H, s), 4.63 (2H, s), 7.66-8.59 (4H, m), 11.90 (1H, bs)
To a mixture of the product obtained in Example 67 (11.3 g) and copper (I) cyanide (4.1 g) was added pyridine (42 ml). After stirring at 70° C. for 17 hours, a solution of Iron (IIl) chloride hexahydrate (15.7 g) in concentrated hydrochloric acid (3.9 ml) and water (23.6 ml) was added slowly to the solution and the resultant mixture was heated with stirring for 5 minutes at 50° C. The formed precipitate was separated by filtration and the filtrate was extracted with ethyl acetate (300 ml) and the organic layer was washed with successive water and saturated aqueous NaCl solution and dried over anhydrous sodium sulfate. Above mentioned precipitate was extracted by ethanol and this ethanol solution was combined with above mentioned organic layer. The resulting solution was concentrated in vacuo and purified by silica gel column chromatography to give 1.21 g of the objective compound.
Melting point: 238.9°-242.5° C.
IR (KBr, cm-1): 2233, 1807, 1746, 1736, 1388, 1167
NMR (DMSO-d6, ppm): 4.51 (2H, s), 7.70-8.47 (4H, m), 11.83 (1H, bs)
A mixture of the product obtained in Example 83 (2.5 g), acetic acid (7 ml) and 47% hydrobromic acid (8.9 ml) was stirred for 1 hour at room temperature and heated for 1 hour at 40° C., for more 1 hour at 50° C. To the mixture was added additional acetic acid (7 ml) and 47% hydrobromic acid (8.9 ml) and heated with stirring for 1 hour at 60° C., for 2 hours at 80° C. The resulting solution was poured into water (300 ml) and extracted with ethyl acetate (1.2 l). After drying over anhydrous magnesium sulfate, ethyl acetate was removed in vacuo and the residue was dissolved in acetone (800 ml). After decoloring with activated charcoal, acetone was removed in vacuo and the residue was washed with successive ethyl acetate and ether to give 1.13 g of the objective compound.
Melting point: 171.8° C. (decomposition)
IR (KBr, cm-1): 3260, 1800, 1735, 1358, 1185, 1164
NMR (DMSO-d6, ppm): 4.60 (2H, s), 7.46-8.19 (4H, m), 11.70 (1H, bs)
A mixture of the product obtained in Example 87 (0.84 g) and 80% (v/v) sulfuric acid (16.3 ml) was heated with stirring for 8 hours at 70° C. and the resulting solution was poured into ice-water (200 ml). The formed precipitate was separated by filtration and washed with successive water, ethanol and acetone to give 0.16 g of the objective compound.
Melting point: 241.9°-244.6° C.
IR (KBr, cm-1): 3412, 3197, 1795, 1741, 1376, 1162
NMR (DMSO-d6, ppm): 4.51 (2H, s), 7.56-8.44 (6H, m), 11.73 (1H, bs)
To a suspension of the product obtained in Example 89 (0.60 g) in concentrated sulfuric acid (18 ml) was added sodium nitrite (2.4 g) under cooling at -15° C. and the resulting suspension was stirred for 15 minutes at -15° C., for 30 minutes at 0° C. and for 50 minutes at room temperaiure. To the mixture was added additional sodium nitrite (1.2 g) and stirred for 30 minutes at room temperature. After adjusting a pH of the resulting solution to ca. 9 with 0.1 M sodium bicarbonate, the resulting solution was washed with ethyl acetate and acidified with concentrated hydrochloric acid to a pH about 2 and extracted with ethyl acetate (200 ml). The organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ethyl acetate was removed in vacuo and the residue was purified by silica gel column chromatography to give 0.18 g of the objective compound.
Melting point: 228.8°-235.1° C.
IR (KBr, cm-1): 3450, 1739, 1735, 1380, 1175
NMR (DMSO-d6, ppm): 4.73 (2H, s), 7.45-8.17 (4H, m), 11.76 (1H, bs)
To a solution of 3-chlorobenzo[b]furan (11.4 g) in anhydrous ether (62 ml) was added dropwise 1.5M lithium diisopropylamide mono(tetrahydrofuran) in hexane (62 ml) under nitrogen atmosphere at -70° C. After stirring for 30 minutes, into the solution was bubbled sulfur dioxide for 1 hour with stirring at -60° C. Then the solution was stirred for 1 hour at room temperature and the formed precipitate was separated by filtration to give lithium 3-chlorobenzo[b]furan-2-sulfidate. To the suspension of the product in dichloromethane (250 ml) was added N-chlorosuccinimide (11.0 g) at -50° C. and stirred for 3 hours. After stirring for 2 hours under ice-cooling. insoluble matters were filtered off. Dichloromethane was removed in vacuo and the residue was purified by silica gel column chromatography to give 8.8 g of the objective compound.
Melting point: 60.6°-68.2° C.
IR (KBr, cm-1): 1538, 1402, 1232, 1183, 1151, 1039
NMR (CDCl3, ppm): 7.40-7.98 (4H, m)
To a suspension of 3-chlorobenzo[b]furan-2-ylsulfonyl chloride (8.6 g) and glycine ethyl ester hydrochloride (9.6 g) in dichloromethane (83 ml) was added slowly triethylamine (10.4 ml) under ice-cooling and then the resulting mixture was stirred for 30 minutes at room temperature. Water (150 ml) was added to the resultant solution and acidified with 1M hydrochloric acid to a pH 2, and the acidified solution was extracted with ethyl acetate (300 ml). After drying over anhydrous magnesium sulfate, ethyl acetate was removed in vacuo to give 10.2 g of the objective compound.
Melting point: 104.5°-110.8° C.
IR (KBr, cm-1): 3203, 1736, 1365, 1230, 1149
NMR (DMSO-d6, ppm): 1.01 (3H, t, J=7.1 Hz), 3.89 (2H, q, J=7.1 Hz), 3.94 (2H, s), 7.50-7.73 (4H, m), 9.12 (1H, bs)
To a solution of N-(3-chlorobenzo[b]furan-2-ylsulfonyl)glycine ethyl ester (10.2 g) in tetrahydrofuran (160 ml) was added dropwise a solution of sodium hydroxide (4.9 g) in water (16 ml) under ice-cooling and the resulting solution was stirred for 1 hour. After stirring for 30 minutes at room temperature, tetrahydrofuran was removed in vacuo. Water (200 ml) was added to the residue and then acidified with concentrated hydrochloric acid under ice-cooling to a pH1 and the acidified solution was extracted with ethyl acetate (500 ml). The organic layer was washed with saturated aqueous NaCl solution. After drying over anhydrous magnesium sulfate, ethyl acetate was removed in vacuo to give 9.2 g of the objective compound.
Melting point: 163.8°-167.9° C.
IR (KBr, cm-1 : 3236, 1709, 1369, 1232, 1153
NMR (DMSO-d6, ppm): 3.84 (2H, d, J=5.9 Hz), 7.38-7.81 (4H, m), 9.03 (1H, t, J=5.9 Hz), 12.67 (1H, bs)
To a mixture of N-(3-chlorobenzo[b]furan-2-ylsulfonyl)glycine (9.2 g), ammonium thiocyanate (5.32 g) and acetic anhydride (18 ml) was added dropwise pyridine (6.68 ml) under ice-cooling and resulting mixture was stirred for 30 minutes at room temperature, for 30 minutes at 40° C. and for 2 hours at 70°-80° C. After coolivg to room temperature, the resulting solution was poured into ice-water (300 ml) and the formed precipitate was separated by filtration and washed with water-ethanol to give 6.73 g of the objective compound.
Melting point: 195.4°-204.7° C.
IR (KBr, cm-1): 3158, 1758, 1393, 1234, 1179
NMR (DMSO-d6, ppm): 4.83 (2H, s), 7.56-7.90 (4H, m)
To a suspension of iodine monochloride (5.3 ml) in 1M hydrochloric acid (160 ml) was added 1-(3-chlorobenzo[b]furan-2-ylsulfonyl)-2-thiohydantoin (6.7 g) and then dichloromethane (200 ml) dropwise. The mixture was stirred for 1.5 hours under ice-cooling and for 1.5 hours at room temperature. After adding saturated aqueous sodium sulfite solution, the reaction mixture was extracted with ethyl acetate (600 ml). The organic layer was washed with successive saturated aqueous sodium sulfite solution and saturated aqueous NaCl solution. After drying over anhydrous magnesium sulfate, ethyl acetate was removed in vacuo and the residue was washed with successive ether and ether-ethyl acetate to give 3.15 g of the objective compound.
Melting point: 246.6°-256.8° C.
IR (KBr, cm-1): 3226, 1744, 1397, 1363, 1174, 1156
NMR (DMSO-d6, ppm): 4.51 (2H, s), 7.54-7.89 (4H, m), 11.81 (1H, bs)
To a suspension of 60% sodium hydride. (60 g) in N,N-dimethylformamide (1.4 l) was added dropwise 3-bromophenol (260 g) under ice-cooling. After stirring for 10 minutes, to the solution was added dropwise bromoacetaldehyde dimethyl acetai (318 g) and the mixture was heated with stirring for 3 hours at 90° C. After cooling, water was added to the resulting solution and acidified with 1 M hydrochloric acid and then extracted with ether (3l). The organic layer was washed with successive water, saturated aqueous sodium bicarbonate solution and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ether was removed in vacuo and the residue was purified by silica gel column chromatography to give 363.3 g of the objective compound.
IR (neat, cm-1): 2941, 2835, 1615, 1506, 1458
NMR (CDCl3, ppm): 3.44 (6H, s), 3.96 (2H, d, J=5.0 Hz), 4.69 (1H, t, J=5.0 Hz), 6.77-7.26 (4H, m)
Under ice-cooling, to phosphoric acid (413.5 ml) was added phosphorus pentoxide (344.2 g) and then chlorobenzene (870 ml). The resulting mixture was heated up to 125° C. To the mixture was added dropwise the solution of the product obtained in Step 1 (181.7 g) in chlorobenzene (150 ml) at 125° C. and heated with stirring for 1 hour at 12:5° C. After cooling, the resulting mixture was poured into ice-water (2l) and extracted with ether (2l). The organic layer was washed with successive saturated aqueous sodium bicarbonate solution and saturated aqueous NaCl solution. After drying over anhydrous sodium suifate, ether and chlorobenzene were removed in vacuo and the residue was purified by silica gel column chromatography to give 116 g of the objective compound.
To a solution of the mixture obtained in Step 2 (100 g) in anhydrous ether (430 ml) was added dropwise 1.5 M lithium diisopropylamide mono(tetrahydrofuran) in cyclohexane (430 ml) under nitrogen atmosphere at -70° C. After stirring for 30 minutes, into the solution was bubbled sulfur dioxide for 1 hour with stirring at -60° C. Then the solution was stirred for 3 hours at room temperature and the formed precipitate was separated by filtration to give a mixture of lithium 4-bromobenzo[b]furan-2-sulfinate and lithium 6 bromobenzo[b]furan-2-sulfinate. To the suspension of the products in dichloromethane (2l) was added N-chlorosuccinimide (96 g) at -50° C. and stirred for 3 hours under ice-cooling. Insoluble matters were filtered off and dichloromethane was removed in vacuo and the residue was purified by silica gel column chromatography to give 14.1 g of the objective compound.
Melting point: 87.2° C.
IR (KBr, cm-1): 1603, 1578, 1389, 1175, 1165
NMR (CDCl3, ppm): 7.43-7.67 (4H, m)
Starting from the product obtained in Step 3 (14.1 g), the objective compound (16.8 g) was obtained in a manner similar to Step 2 of Example 91.
Melting point: 115.6°-117.3° C.
IR (KBr, cm-1): 3199, 1361, 1221, 1158
NMR (CDCl3, ppm): 1.18 (3H, t, J=7.1 Hz), 3.97 (2H, d, J=5.3 Hz), 4.09 (2H, q, J=7.1 Hz), 5.45 (1H, t, J=5.3 Hz), 7.26-7.58 (4H, m)
Starting from the product obtained in Step 4 (16.8 g), the objective compound (14.4 g) was obtained in a manner similar to Step 3 of Example 91.
Melting point: 180.0°-182.1° C.
IR (KBr, cm-1): 3253, 1738, 1361, 1262, 1165
NMR (DMSO-d6, ppm): 3.81 (2H, s), 7.38-7.81 (4H, m), 8.85 (1H, bs)
To a suspension of the product obtained in Step 5 (14.4 g) and ammonium thiocyanate (7.2 g) in acetic anhydride (28 ml) was added dropwise pyridine (9.1 ml) and the mixture was heated with stirring for 2 hours at 60°-70° C. After cooling to room temperature, the resulting solution was poured into ice-water (500 ml) and the formed precipitate was separated and washed with ethanol to give 10.7 g of the objective compound.
Melting point: 253.3° C.
IR (KBr, cm-1): 3140, 1756, 1391, 1248, 1166
NMR (DMSO-d6, ppm): 4.77 (2H, s), 7.45-7.88 (3H, m), 7.95 (1H, s), 12.86 (1H, bs)
Starting from the product obtained in Step 6 (10.7 g), the objective compound (4.3 g) was obtained in a manner similar to Step 5 of Example 91.
Melting point: 291.7°-293.5° C.
IR (KBr, cm-1): 3240, 1741, 1390, 1355, 1167
NMR (DMSO-d6, ppm): 4.48 (2H, s), 7.45-7.90 (4H, m), 11.78 (1H, t,s)
Starting from 7-fluorobcnzo[b]furan (10.4 g), the objective compound (5.7 g) was obtained in a manner similar to Step 1 of Example 91.
Melting point: 114° C.
IR (KBr, cm-1): 1596, 1546, 1372, 1267, 1178
NMR (CDCl3, ppm): 7.24-7.69 (4H, m)
Starting from the product obtained in Step 1 (5.7 g), the objective compound (6.45 g) was obtained in a manner similar to Step 2 of Example 91.
Melting point: 84.5° C.
IR (KBr, cm-1): 3238, 1734, 1376, 1232. 1165
NMR (DMSO-d6, ppm): 1.03 (3H, t, J=7.1 Hz), 3.89 (2H, d, J=6.3 Hz), 3.92 (2H, q. J=7.1 Hz), 7.32-7.66 (4H, m), 9.05 (1H, t, J=6.3 Hz)
Starting from the product obtained in Step 2 (6.4 g), the objective compound (5.42 g) was obtained in a manner similar to Step 3 of Example 91.
Melting point: 140.1° C. (decomposition)
IR (KBr, cm-1): 3303, 1734, 1349, 1262, 1160
NMR (DMSO-d6, ppm): 3.80 (2H, d, J=5.0 Hz), 728-7.66 (4H, m), 8.90 (1H, t, J=5.0 Hz)
To a suspension of the product obtained in Step 3 (5.4 g) and ammonium thiocyanate (3.32 g) in acetic anhydride (12.7 ml) was added dropwise pyridine (4.16 ml) under ice-cooling and nitrogen atmosphere. The mixture was heated with stirring for 2 hours at 70° C. After cooling to room temperature, the resulting solution was poured into ice-water (200 ml) and added small amount of ethanol and the formed precipitate was separated and dissolved in ethyl acetate (200 ml) and the solution was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ethyl acetate was removed in vac and the residue was washed with ethanol to give 2.83 g of the objective compound.
Melting point: 229.9°-232.0° C.
IR (KBr, cm-1): 3258, 1765, 1744, 1448, 1177
NMR (DMSO-d6, ppm): 4.73 (2H, s), 7.39-7.77 (3H, m), 8.13 (1H, d, J=2.6 Hz), 12.83 (1H, bs)
Starting from the product obtained in Step 4 (2.8 g), the objective compound (1.1 g) was obtained in a manner similar to Step 5 of Example 91.
Melting point: >300° C.
IR (KBr, cm-1): 5381, 1735, 1610, 1383, 1166
NMR (DMSO-d6, ppm): 3.98 (2H, s), 7.34-7.71 (3H, m), 7.78 (1H, d, J=3.0 Hz)
Starting from 3,4-dichlorophenol (200 g), the objective compound (218.8 g) was obtained in a manner similar to Step 1 of Example 92.
IR (neat, cm-1): 2940, 2830, 1595, 1475, 1297, 1235
NMR (CDCl3, ppm): 3.45 (6H, s), 3.96 (2H, d, J=5.3 Hz), 4.69 (1H, t, J=5.3 Hz), 6.78 (1H, dd, J=8.9, 3.0 Hz), 7.02 (1H, d, J=3.0 Hz), 7.31 (1H, d, J=8.9 Hz)
Starting from the product obtained in Step 1 (218.8 g), the mixture of the objective compounds (102.1 was obtained in a manner similax to Step 2 of Example 92.
To a solution of the mixture obtained in Step 2 (100 g) in anhydrous ether (440 ml) was added dropwise 1.5 M lithium diisopropylnmide mono(tetrahydrofuran) in cyclohexane (440 ml) under nitrogen atmosphere at -70° C. over 1 hour, then into the solution was bubbled sulfur dioxide for 1.5 hours at -70° C. After stirring for 1 hour at room temperature, the solvent was removed in vacuo and ether was added to the residue. The formed precipitate was separated by filtration to give a mixture of lithium 4,5-dichlorobenzo[b]furan-2-sulfinate and lithium 5,6-dichlorobenzo[b]furan-2-sulfinate. To the suspension of the products in dichloromethane (1.8 l) was added N-chlorosuccimimide (92.1 g) at -50° C. and stirred for 1.5 hours. At room temperature, insoluble matters were filtered off and dichloromethane was removed in vacuo and the residue was purified by silica gel column chromatography to give 17.4 g of 4,5-dichlorobenzo[b]furan-2-ylsulfonyl chloride and 7.4 g of 5,6-dichlorobenzo[b]furan-2-ylsulfonyl chloride, respectively. 4,5-dichlorobenzo[b]furan-2-ylsulfonyl chloride
Melting point: 114.6° C.
IR (KBr, cm-1, ppm), 1529, 1444, 1401, 1191
NMR (DMSO-d6, ppm): 6.87 (1H, d, J=1.0 Hz), 7.55 (1H, d, J=8.9 Hz), 7.69 (1H, dd, J=8.9, 1.0 Hz) 5,6-dichlorobenzo[b]furan-2-ylsulfonyl chloride
Melting point: 159.8° C.
IR (KBr, cm-1): 1537, 1390, 1163, 1081
NMR (DMSO-d6, ppm): 6.87 (1H, d, J=1.0 Hz), 7.92 (1H, s), 8.02 (1H, d, J=1.0 Hz)
Starting from 4,5-dichlorobenzo[b]furan-2-ylsulfonyl chloride obtained in Step 3 (17 g), the objective compound (18.2 g) was obtained in a manner similar to Step 2 of Example 91.
Melting point: 155.2°-155.5° C.
IR (KBr, cm--1): 3199, 1737, 1225, 1160
NMR (CDCl3, ppm): 1.05 (3H, t, J=7.1 Hz), 3.92 (2H, s), 3.95 (2H, q, J=7.1 Hz), 7.56 (1H, s), 7.78 (2H, s), 9.09 (1H, bs)
Starting from the product obtained in Step 4 (18 g), the objective compound (16.2 g) was obtained in a manner similar to Step 3 of Example 91.
Melting point: 189.8°-194.7° C.
IR (KBr, cm-1): 3320, 1719, 1366, 1256, 1162
NMR (DMSO-d6, ppm): 3.83 (2H, d, J=6.3 Hz), 7.56 (1H, s), 7.76 (2H, s), 8.97 (1H, t, J=6.3 Hz)
Starting from the product obtained in Step 5 (16 g), the objective compound (7.4 g) was obtained in a manner similar to Step 4 of Example 91.
Melting point: 214.6°-217.5° C.
IR (KBr, cm-1): 1793, 1762, 1445, 1167
NMR (DMSO-d6, ppm): 4.77 (2H, s), 7.85 (2H, s), 8.11 (1H, s), 12.95 (1H, bs)
To a suspension of iodine monochloride (6.3 ml) in 1 M hydrochloric acid (150 ml) were added successively the product obtained in Step 6 (7.3 g) and dropwise dichloromethane (150 ml) over 10 minutes. The mixture was stirred for 2.5 hours at room temperature. Under ice-cooling, to the solution was added saturated aqueous sodium sulfite solution and stirred for a while. The formed precipitate was separated by filtration and washed with successive water, ethanol and ether to give 4.8 g of the objective compound.
Melting point: 290.7°-292.0° C. (decomposition)
IR (KBr, cm-1): 3256, 1742, 1391, 1356, 1168
NMR (DMSO-d6, ppm): 4.47 (2H, s), 7.85 (2H, s), 7.98 (1H, s), 11.80 (1H, bs)
To a solution of 5,6-dichlorobenzo[b]furan-2-ylsulfonyl chloride obtained in Step 3 of Example 64 (7.4 g) in dichleromethane (60 ml) was added glycine ethyl ester hydrochloride (7.95 g) and added slowly triethylamine (7.89 ml) under ice-cooling and nitrogen atmosphere. The resulting solution was poured into water (100 ml) and acidified with 1 M hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated aqueous NaCl solution and dried over anhydrous sodium sulfate. Ethyl acetate was removed in vacuo and the residue was washed with hexane to give 8.7 g of the objective compound.
Melting point: 132.7°-133.5° C.
IR (KBr, cm-1): 3227, 1735, 1360. 1225, 1158
NMR (DMSO-d6, ppm): 1.06 (3H, t, J=6.9 Hz), 3.90 (2H, s), 3.95 (2H, q, J=6.9 Hz), 7.52 (1H, s), 8.08 (1H, s), 8.20 (1H, s), 9.05 (1H, b)
Starting from the product obtained in Step 1 (8.6 g), the objective compound (7.8 g) was obtained in a manner similar to Step 3 of Example 91.
Melting point: 192.6°-201.8° C.
IR (KBr, cm-1): 3367, 1719, 1359, 1248, 1159
NMR (DMSO-d6, ppm): 3.80 (2H, d, J=5.9 Hz), 7.51 (1H, d, J=1.0 Hz), 8.08 (1H, s), 8.19 (1H, d, J=-- 1.0 Hz), 8.92 (1H, t, J=5.9 Hz)
Starting from the product obtained in Step 2 (7.7 g), the objective compound (3.7 g) was obtained in a manner similar to Step 4 of Example 91.
Melting point: >246.0° C. (decomposition)
IR (KBr, cm-1): 3100, 1743, 1449, 1246, 1166
NMR (DMSO-d6, ppm): 4.73 (2H, s), 8.02 (1H, d, J=1.0 Hz), 8.20 (1H, s), 8.26 (1H, d, J=1.0 Hz), 12.82 (1H, bs)
Starting from the product obtained in Step 3 (3.7 g), the objective compound (2.7 g) was obtained in a manner similar to Step 5 of Example 91.
Melting point: >300° C. (decomposition)
IR (KBr, cm-1): 1732, 1389, 1186, 1167
NMR (DMSO-d6, ppm): 4.31 (2H, s), 7.82 (1H, d, J=0.7 Hz), 8.16 (1H, s), 8.27 (1H, d, J=0.7 Hz)
To a solution of 7-fluorobenzo[b]furan (16 g) in carbon tetrachloride (40 ml) was added dropwise a solution of bromine (22 g) in carbon disulfide (40 ml) at -30° C. and the solution was stirred for 1 hour. At room temperature, the formed precipitate was separated by filtration to give 34.4 g of the objective compound.
IR (KBr, cm-1): 1634, 1601, 1489, 1459, 1279, 1179
NMR (CDCl3, ppm): 5.74 (1H, d, J=1.3 Hz), 6.93 (1H, s). 7.11-7.35 (3H, m)
To a solution of potassium hydroxide (12.7 g) in ethanol (180 ml) was slowly added the product obtained in Step 1 (34 g) and stirred for 3 hours. The resulting solution was neutralized by acetic acid, then extracted with ether. The organic layer was washed with successive water and saturated aqueous NaCl solution. After drying over anhydrous sodium sulfate, ether was removed in vacuo to give 24.1 g of the objective compound.
IR (neat, cm-1): 3150, 1636, 1595, 1494, 1434, 1322
NMR (CDCl3, ppm): 6.98-7.36 (3H, m), 7.68 (1H, s)
Starting from the product obtained in Step 2 (24.1 g), the objective compound (12.2 g) was obtained in a manner similar to Step 1 of Example 91.
IR (KBr, cm-1): 1602, 1533, 1385, 1168
NMR (DMSO-d6, ppm): 7.33-7.39 (3H, m)
Starting from the product obtained in Step 3 (12.2 g), the objective compound (10.2 g) was obtained in a manner similar to Step 2 of Example 91.
Melting point: 126.2°-126.4 C.
IR (KBr, cm-1): 3200, 1731, 1366, 1237, 1142
NMR (DMSO-d6, ppm): 1.01 (3H, t, J=7.1 Hz) 3.89 (2H, q, J=7.1 Hz), 3.96 (2H, d, J=5.6 Hz), 7.47-7.66 (3H, m), 9.32 (1H, t, J=5.6 Hz)
Starting from the product obtained in Step 4 (10.2 the objective compound (7.25 g) was obtained in a manner similar to Step 3 of Example 91.
Melting point: 148.5°-159.6° C.
IR (KBr, cm-1): 3223, 1716, 1373, 1246, 1163
NMR (DMSO-d6, ppm): 3.86 (2H, s), 7.46-7.58 m), 9.18 (1H, bs)
Starting from the product obtained in Step 5 (7.2 g), the objective compound (5.07 g) was obtained in a manner similar to Step 4 of Example 91.
Melting point: 224.3°-224.7° C. (decomposition)
IR (KBr, cm-1): 3290, 1793, 1765, 1235, 1141
NMR (DMSO-d 6, ppm): 4.83 (2H, s), 7.57-7.72 (3H, m), 12.93 (1H, bs)
To a suspension of iodine monochloride (3.3 ml) in 1 M hydrochloric acid (110 ml) was added the product obtained in Step 6 (5 g) and dropwise dichloromethane (140 ml). The mixture was stirred for 6 hours at room temperature and then additive iodine monochloride (1.7 ml) was added to the mixture and the resulting mixture was stirred for 1 hour. To the resulting solution was added saturated aqueous sodium sulfite solution and formed precipitate was separated by filtration. The organic layer was washed with saturated aqueous NaCl solution and dried over anhydrous magnesium sulfate. Formed precipitate was suspended in 1 M hydrochloric acid (100 ml) and the suspension was extracted with ethyl acetate. The organic layer was washed with saturated aqueous NaCl solution and dried over anhydrous magnesium sulfate. Both extracts were combined and the solvent was removed in vacuo. The resulting residue was washed with successive ethanol and ether to give 1.66 g of the objective compound.
Melting point: 266.6°-270.6° C.
IR (KBr, cm-1): 3160, 1725, 1393, 1184, 1149
NMR (DMSO-d6, ppm): 4.50 (2H, s), 7.53-7.77 (3H, m), 11.85 (1H, bs)
Compounds of Example 97 to 102 prepared in a manner similar to Example 91 are summarized in the following table 11 together with corresponding IR, and NMR data and melting points.
TABLE 11
__________________________________________________________________________
##STR173##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO)-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
97
##STR174## 1732, 1389 1181, 1166
##STR175## >297 (dec.)
98
##STR176## 3216, 1734, 1397, 1363, 1175, 1151
4.54(2H, s), 7.51˜7.75(4H, m), 11.82(1H,
bs) 292 (dec.)
99
##STR177## 1742, 1394, 1183, 1174, 1153
##STR178## 256.3˜ 258.6 (dec.)
100
##STR179## 3262, 1734, 1397, 1352, 1178, 1170
4.44(2H, s), 7.70(1H, d, J=1.0Hz), 7.71(1H, s),
.22(1H, d, J=1.0Hz)
>249.2 (dec.)
101
##STR180## 3279, 1744, 1404, 1176, 1148
4.51(2H, s), 7.74(1H, d, J=1.7Hz), 8.16(1H, d,
J= 1.7Hz), 11.82(1H, bs)
249.5˜ 251.7
102
##STR181## 3220, 1745, 1407, 1357, 1181, 1152.
4.48(2H, s), 7.58˜7.97(4H,
238.8˜ 240.8
__________________________________________________________________________
Another intermediate compounds of Example 29 to 39, 41 to 48, 50, 52, 54, 63 to 83, 97 to 102 are summarized in the following table 12 to 16 together with corresponding IR and NMR data and melting points.
TABLE 12
__________________________________________________________________________
QSO.sub.2Cl
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
29
##STR182## 1500, 1392, 1216, 1174, 1001
7.12˜8.00(3H, m), 7.43(1H, s)
30
##STR183## 1588, 1493, 1169, 1078
7.55(1H, dd, J=8.9, 1.3Hz), 7.85(1H, d,
J=8.9Hz), 7.95(1H, d, J=1.3Hz), 8.07(1H, s)*
31
##STR184## 1592, 1480, 1391, 1248, 1180
7.37˜8.01(4H, m)
32
##STR185## 1584, 1544, 1493, 1388, 1170, 1007
7.35˜7.95(3H, m), 7.42(1H, s)
33
##STR186## 1530, 1372, 1275, 1240, 1160
7.46˜7.92(3H, m), 7.58(1H, s)*
34
##STR187## 1531, 1394, 1164, 1080, 809
7.50˜7.76(3H, m), 7.59(1H, s)*
35
##STR188## 1508, 1406, 1375, 1320, 1180
2.81(3H, s), 7.74˜8.24(3H, m)
37
##STR189## 1423, 1375, 1172
7.38˜7.72(2H, m), 7.84˜8.01(1H,
m), 8.26˜8.46(1H, m), 8.51(1H, s)*
38
##STR190## 1383, 1170, 750, 590
7.53˜7.72(2H, m), 7.87˜8.03(1H,
m), 8.07˜8.23(1H, m)*
39
##STR191## 2.67(3H, s), 4.13(3H, s), 7.51˜8.03(3H,
m)*
41
##STR192## 1734, 1375, 1169, 1102
##STR193##
42
##STR194## 1415, 1381, 1371, 1237, 1172, 1151
2.81(3H, s), 7.60˜8.06(3H, m),
43
##STR195## 1617, 1383, 1371, 1216, 1173
7.70(1H, dd, J=8.6, 1.0Hz), 7.87(1H, d,
J=8.6Hz), 8.08(1H, d, J=1.0Hz)
44
##STR196## 1604, 1380, 1192, 1161, 534
7.86(1H, d, J=8.9Hz), 8.27(1H, dd, J=8.9,
2.0Hz), 8.55(1H, d, J=2.0Hz), 8.93(1H, s)*
45
##STR197## 1379, 1368, 1314, 1171, 1158
7.50(1H, t, J=7.9Hz), 7.82(1H, d, J=5.6Hz),
8.00˜8.28(3H, m)*
46
##STR198## 1375, 1311, 1202, 1169, 1043
7.47˜8.15(5H, m)
47
##STR199## 7.35˜7.90(5H, m)
48
##STR200## 1457, 1395, 1214, 1166
7.05˜7.14(2H, m), 8.21˜8.24(1H,
m)
50
##STR201## 1625, 1590, 1522, 1377, 1175
8.00˜8.98(4H, m)
52
##STR202## 1590, 1374, 1178, 765
7.36˜7.78(9H, m)
54
##STR203## 2945, 2941, 1453, 1373, 1161
1.23˜2.50(10H, m), 3.39˜3.65(1H,
m)*
63
##STR204## 1479, 1380, 1166, 1000, 548
7.37(1H, dd, J=8.6, 1.3Hz), 7.44(1H, s),
7.84(1H, d, J=8.6Hz), 8.04(1H, d, J=1.3Hz)
64
##STR205## 1493, 1454, 1390, 1167
7.32˜7.53(2H, m), 7.62(1H, s),
7.82˜7.97(1H, m)
65
##STR206## 2968, 2935, 1503, 1465, 1375, 1167
1.59(3H, d, J=7.3Hz), 4,11˜4.44(1H,
m), 7.44˜7.64(2H, m), 7.83˜7.94(1
H, m), 8.19˜8.26(1H, m)*
66
##STR207## 7.42˜8.06(4H, m)
67
##STR208## 1473, 1389, 1177, 533
7.51˜8.11(4H, m)*
68
##STR209## 1737, 1371, 1329, 1201, 1174
##STR210## 90.4˜ 93.2 (dec.)
70
##STR211## 1575, 1530, 1394, 1384, 1174
7.47˜7.69(3H, m)*
116.0˜ 116.9
71
##STR212## 1520, 1395, 1231, 1148
7.31˜7.67(4H, m)
72
##STR213## 1396, 1178, 1049
7.73(1H, s) 101.3˜ 103.0
73
##STR214## 1488, 1384, 1174, 570
7.26˜7.92(3H, m)*
90.0˜ 92.0
74
##STR215## 2948, 1436, 1417, 1166
1.79˜1.94(4H, m), 2.62˜2.85(4H,
m), 7.55(1H, s)*
75
##STR216## 1398, 1242, 1182, 1147, 534
7.31˜7.70(9H, m)*
76.2˜ 77.4
76
##STR217## 1526, 1389, 1370, 1179, 570, 538
7.42˜8.27(4H, m)*
77
##STR218## 6.96(1H, d, J=5.6Hz), 7.66˜7.77(1H,
m)*
78
##STR219## 1478, 1419, 1383, 1178
7.42˜8.41(4H, m)*
79
##STR220## 7.45˜7.85(3H, m), 8.40˜8.50(1H,
m)*
80
##STR221## 1381, 1161, 1086, 775
7.24˜7.85(4H, m)*
82
##STR222## 1377, 1172, 1164, 762, 567
2.58(3H, s), 7.46˜8.25(4H, m)*
83
##STR223## 1510, 1377, 1348, 1175, 578
4.09(3H, s), 7.36˜7.74(4H, m)
97
##STR224## 1533, 1385, 1168, 1077
7.49˜7.71(3H, m), 7.86(1H,
82.1˜ 82.9
98
##STR225## 1507, 1501, 1391, 1225, 1139
7.38˜7.88(4H, m)*
88.3˜ 91.6
101
##STR226## 7.46(1H, d, J=1.7Hz), 7.61(1H, d, J=1.7Hz)*
102
##STR227## 7.46˜7.99(4H, m)*
__________________________________________________________________________
NMR data marked with asterisks (*) were measured in CDCl.sub.3 -
TABLE 13
__________________________________________________________________________
QSO.sub.2 NHCH.sub.2 COOEt
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
97
##STR228## 3340, 1742, 1357, 1204, 1161
1.18(3H, t, J=7.3Hz), 3.96(2H, d, J=5.6Hz),
4.10(2H, q, J=7.3Hz), 5.51(1H, t, J=5.6Hz),
7.35˜7.73(4H m)
81.2˜ 81.5
98
##STR229## 3184, 1738, 1364, 1225
1.00(3H, t, J=7.1Hz), 3.87(2H, q, J=7.1Hz),
3.92(2H, d, J=5.9Hz), 7.45˜7.90(4H, m),
9.03(1H, t, J=5.9Hz)
130.4˜ 134.1
99
##STR230## 3197, 1737, 1366, 1229, 1162
1.19(3H, t, J=7.1Hz), 4.02(2H, d, J=6.6Hz),
4.10(2H, d, J=7.1Hz), 5.64(1H, t, J=6.6Hz),
7.24˜7.63(3H, m)
129.4˜ 130.6
100
##STR231## 3295, 1732, 1366, 1232, 1147
##STR232## 132.9˜ 133.4
101
##STR233## 3236, 1731, 1365, 1233, 1148
1.20(3H, t, J=7.1Hz), 4.02(2H, d, J=4.9Hz),
4.11(2H, q, J=7.1Hz), 5.62(1H, t, J=4.9Hz),
7.38(1H, d, J=1.7Hz), 7.51(1H, d,
167.3˜ 169.2
102
##STR234## 3202, 1739, 1371, 1228, 1171
1.00(3H, t, J=6.9Hz), 3.90(2H, q, J=6.9Hz),
3.99(2H, d, J=6.6Hz), 7.44˜7.89(4H, m),
9.39(1H, t, J=6 6Hz)
135.6˜ 147.8
__________________________________________________________________________
TABLE 14
__________________________________________________________________________
QSO.sub.2 NHCH.sub.2 CO.sub.2 H
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
63
##STR235## 3.74(2H, s), 7.48˜8.27(4H, m),
8.55(1H, bs)
210.1˜ 213.3
64
##STR236## 3270, 1732, 1394, 1354, 1260, 1160
3.76(2H, d, J=5.9Hz), 7.38˜8.09(4H,
m), 8.65(1H, t, J=5.9Hz), 12.74(1H,
193.0˜ 205.0
65
##STR237## 3312, 2980, 2968, 1726, 1321, 1143
1.45(6H, d, J=7.3Hz), 3.72(2H, d, J=4.3Hz),
3.84˜4.17(1H, m), 7.42˜8.30(4H,
m), 8.61(1H, t, J=4.3Hz)
110.0˜ 115.5
66
##STR238## 3354, 1730, 1421, 1361, 1214, 1164, 1122
3.73(2H, s), 7.57˜8.25(4H,
141.3˜ 144.5
67
##STR239## 3304, 1725, 1709, 1487, 1353, 1249, 1160
3.86(2H, d, J=5.9Hz), 7.57˜81.9(4H,
m), 8.81(1H, t, J=5.9Hz)
149.1˜ 153.3
68
##STR240## 3294, 1735, 1158
##STR241## 125.0˜ 126.9
69
##STR242## 3280, 1734, 1372, 1347, 1312, 1255, 1167
3.72(2H, d, J=5.3Hz), 7.61(1H, s), 8.55(1H,
t, J=5.3Hz), 12.85(1H, bs)
200.5˜ 202.0
70
##STR243## 3275, 1718, 1364, 1161
3.82(2H, d, J=5.9Hz), 7.53(1H, s), 7.63(1H,
d, J=1.6Hz), 7.99(1H, bs), 8.95(1H, t,
J=5.9Hz) 194.2˜ 196.4
71
##STR244## 1717, 1709, 1437, 1369, 1150
3.82(2H, d, J=5.9Hz), 7.36˜7.80(4H,
m), 8.95(1H, t, J=5.9Hz).
153.4˜ 156.1
72
##STR245## 3340, 1718, 1321, 1252, 1153, 1141, 1130
3.79(2H, d, J=5.9Hz), 8.17(1H, s), 8.72(1H,
t, J=5.9Hz), 12.82(1H, bs)
203.5˜ 205.2
73
##STR246## 3344, 1713, 1498, 1341, 1247, 1163
3.88(2H, d, J=6.3Hz), 7.43˜7.82(3H,
m), 8.98(1H, t, J=6.3Hz)
194.0˜ 201.0
74
##STR247## 3315, 3201, 2433, 1752, 1443, 1326, 1187,
1.50˜1.98(4H, m), 2.40˜2.88(4H,
m), 3.59(2H, d, J=4.9Hz), 7.26(1H, s),
8.08(1H, t, J=4.9Hz)
141.2˜ 143.2
75
##STR248## 3265, 1716, 1352, 1236, 1169, 1139
3.74(2H, s), 7.08˜7.81(9H, m),
8.72(1H, bs)
151.4˜ 153.7
76
##STR249## 3290, 1742, 1375, 1255, 1173, 1118
3.82(2H, d, J=5.9Hz), 7.45˜8.16(4H,
m), 8.84(1H, t, J=5.9Hz), 12.72(1H,
129.7˜ 134.2
77
##STR250## 3306, 3117, 1732, 1546, 1424, 1412, 1336,
##STR251## 167.4˜ 169.4
78
##STR252## 3264, 1725, 1420, 1350, 1249, 1160
3.74(2H, d, J=5.6Hz), 7.45˜8.31(4H,
m), 8.60(1H, t, J=5.6Hz), 12.51(1H,
126.0˜ 129.5
79
##STR253## 1747, 1589, 1367, 1198
4.30(2H, d, J=5.9Hz), 7.21˜8.34(4H,
m), 9.94(1H, t, J=5.9Hz)
212.4 (dec.)
80
##STR254## 3265, 1717, 1362, 1248, 1159
3.83(2H, d, J=5.9Hz), 7.22˜7.84(4H,
m), 8.85(1H, t, J=5.9Hz), 12.66(1H,
222.9˜ 227.1
81
##STR255## 3290, 1707, 1560, 1338, 1167
2.16(3H, s), 2.43(3H, s), 3.65(2H, d,
J=6.3Hz), 8.27(1H, t, J=6.3Hz), 12.45(1H,
bs) 247.0 (dec.)
97
##STR256## 3312, 1719, 1353, 1249, 1165
3.77(2H, s), 7.49˜7.79(3H, m),
8.04(1H, s), 8.79(1H, bs)
186.5
98
##STR257## 3230, 1709, 1368, 1238, 1173
3.82(2H, d, J=5.9Hz), 7.44˜7.73(4H,
m), 8.88(1H, t, J=5.9Hz)
179.4˜ 183.0
99
##STR258## 3280, 1716, 1369, 1238, 1168
##STR259## 222.9˜ 227.1
100
##STR260## 3338, 1731, 1365, 1234, 1166
3.83(2H, bs), 7.63(2H, s), 8.14(1H, s),
9.00(1H, bs)
210.4˜ 212.0
101
##STR261## 3238, 1717, 1369, 1171, 1151
3.86(2H, d, J=6.3Hz), 7.66(1H, d, J=1.7Hz),
8.07(1H, d, J=1.7Hz), 9.15(1H, t,
239.1˜ 241.3
102
##STR262## 3247, 1716, 1373, 1239, 1173
3.89(2H, d, J=6.3Hz), 7.50˜7.91(4H,
m), 9.30(1H, t, J=6.3Hz)
162.0˜ 178.1
__________________________________________________________________________
TABLE 15
__________________________________________________________________________
QSO.sub.2 NHCH.sub.2 CONH.sub.2
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
82
##STR263## 3434, 3308, 3188, 1703, 1366, 1155
2.46(3H, s), 3.67(2H, d, J=4.6Hz), 7.10(1H,
bs), 7.30(1H, bs), 7.53˜8.16(5H,
180.4˜ 181.1
83
##STR264## 3392, 1672, 1522, 1354, 1333, 1153, 1139
3.60(2H, s), 4.10(3H, s), 7.05(1H, bs),
7.20(1H, bs), 7.53˜8.16(5H,
162.0˜ 163.1
__________________________________________________________________________
TABLE 16
__________________________________________________________________________
##STR265##
Ex. M.P.
No.
Q IR(KBr, cm.sup.-1)
NMR(DMSO-d.sub.6, ppm)
(°C.)
__________________________________________________________________________
63
##STR266## 3320, 1800, 1769, 1458, 1370, 1230
##STR267## 249.6 (dec.)
64
##STR268## 3110, 1791, 1751, 1745, 1381, 1180
4.76(2H, s), 7.50˜7.82(1H, m),
8.11(1H, dd, J=7.6, 1.3Hz), 8.57(1H, s),
12.79(1H, bs)
221.0 (dec.)
65
##STR269## 3140, 1791, 1757, 1459, 1346, 1177
1.43(6H, d, J=6.9Hz), 3.63˜3.96(1H,
m), 7.47˜7.61(1H, m), 8.07˜8.31(1
H, m), 12.84(1H, bs)
191.3˜ 195.7
66
##STR270## 3120, 1756, 1465, 1366, 1175, 1164
4.76(2H, s), 7.60˜8.38(4H, m),
13.01(1H, bs)
232.1˜ 233.5
67
##STR271## 3180, 1782, 1755, 1455, 1372, 1170
4.95(2H, s), 7.56˜8.32(4H, m),
12.92(1H, bs)
222.8 (dec.)
68
##STR272## 3220, 1756, 1726, 1376, 1173
##STR273## 204.7 (dec.)
69
##STR274## 1793, 1473, 1392, 1191, 1174
4.69(2H, s), 8.07(1H, s), 12.78(1H,
203.0 (dec.)
70
##STR275## 3292, 1795, 1765, 1464, 1381, 1185, 1176
4.74(2H, s), 7.73(1H, d, J=1.7Hz), 8.06.about
.8.09(2H, m) 12.87(1H, bs)
211.6 (dec.)
71
##STR276## 1795, 1759, 1460, 1384, 1149
4.83(2H, s), 7.43˜7.89(4H, m),
12.96(1H, bs)
212.8˜ 219.9 (dec.)
72
##STR277## 3350, 1793, 1764, 1458, 1362, 1174
4.87(2H, s), 8.44(1H, s), 12.88(1H,
242.0 (dec.)
73
##STR278## 3289, 1795, 1770, 1492, 1458, 1359, 1180, 1156,
4.97(2H, s), 7.55˜7.88(3H, m),
13.01(1H, bs)
254.0 (dec.)
74
##STR279## 3157, 1794, 1765, 1376, 1352, 1161
1.50˜1.94(4H, m), 2.46˜2.94(4H,
m), 4.65(2H, s), 7.72(1H, s), 12.61(1H,
245.0˜ 246.8
75
##STR280## 1786, 1750, 1446, 1370, 1348, 1178
4.37(2H, s), 7.13˜7.90(9H, m),
12.82(1H, bs)
183.8 (dec.)
76
##STR281## 3130, 1790, 1759, 1383, 1182
4.73(2H, s), 7.57˜8.15(4H, m),
12.81(1H, bs)
230.5˜ 223.8
77
##STR282## 3107, 1755, 1537, 1469, 1423, 1376, 1248,
4.66(2H, s), 7.21(1H, d, J=5.6Hz), 8.16(1H,
dd, J=5.6, 4.3Hz).
194.4 (dec.)
78
##STR283## 3268, 1790, 1765, 1459, 1348, 1178, 1160
4.93(2H, s), 7.50˜7.73(2H, m),
8.04˜8.29(2H, m), 12.82(1H,
244.0˜ 246.0
79
##STR284## 1790, 1763, 1460, 1348, 1182
4.68(2H, s), 7.59˜7.70(2H, m),
8.14˜8.40(2H, m), 12.68(1H,
710.0 (dec.)
80
##STR285## 3215, 1744, 1456, 1332, 1162
4.77(2H, s), 7.30˜7.91(4H, m),
12.85(1H, bs)
210.9 (dec.)
81
##STR286## 3180, 1761, 1535, 1371, 1170
2.19(3H, s), 2.54(3H, s), 4.68(2H, s),
12.64(1H, bs), 12.75(1H, bs)
250.0 (dec.)
97
##STR287## 3319, 1794, 1766, 1461, 1163
4.73(2H, s), 7.63(1H, d, J=8.6Hz), 7.85(1H,
d, J=8.6Hz), 8.05(1H, s), 8.12(1H,
246.8˜ 247.7
98
##STR288## 1735, 1397, 1228, 1173
4.88(2H, s), 7.56˜7.90(4H, m),
13.04(1H, bs)
195˜ 198
99
##STR289## 3330, 1792, 1764, 1456, 1174
##STR290## 219.5˜ 222.3
100
##STR291## 3084, 1749, 1388, 1266, 1182
4.81(2H, s), 7.70(1H, s), 7.72(1H, s),
8.22(1H, s) >240 (dec.)
101
##STR292## 3568, 1752, 1382, 1244, 1177
4.84(2H, s), 7.76(1H, d, J=1.6Hz), 8.17(1H,
d, J=1.6Hz), 13.15(1H, bs)
220 (dec.)
102
##STR293## 3110, 1752, 1239, 1178, 1174
4.83(2H, s), 7.60˜7.99(4H,
161.6˜ 179.3
__________________________________________________________________________
Compound 38, 250 g of weight, 730 g of lactose and 20 g of magnesium stearate were weighed and mixed until the mixture became homogeneous. The mixture was then filled in No. 1 hard gelatin capsule at 200 mg each to obtain capsule preparation.
Compound 34, 300 g of weight, 550 g of lactose, 120 g of potato starch, 15 of polyvinyl alcohol and 15 g of magnesium stearate were weighed. The weighed amount of compound 34, lactose and potato starch were mixed until accomplishing homogeneity. Then aqueous solution of polyvinylalcohol was added to the mixture and granulated by wet process. The granules were then dried, mixed with magnesium stearate and pressed into tablets, each weighing 200 mg.
Compound 46, 200 g of weight, 790 g of lactose and 10 g of magnesium stearate were weighed and mixed until the mixture became homogeneous to obtain 20% powder preparation.
Compound 44, 100 g or weight were weighed and ground by a mortar until the compound became fine powder. Then 180 g of polyethylene glycol 1500 and 720 g of polyethylene glycol 4000 were added to the compound and melted. The mixture was then pressed at 1 g each to obtain suppository preparation.
Claims (16)
1. A sulfonylglycine derivative represented by the formula (IV):
Q--SO.sub.7 NHCH.sub.7 CO--R (IV)
wherein R represents a hydroxy group, an alkoxy group or an amino group which may be substituted with an alkoxycarbonyl group, Q represents a benzo[b]furan-2-yl group which may be substituted by one or more substituents which are the same or different and selected from the group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an optionally protected hydroxy group other than a lower alkoxy group, an optionally protected amino group, a carbamoyl group and a phenyl group.
2. A sulfonylglycine derivative as claimed in claim 1, wherein said substituents are 1 to 3 halogen atoms. .[.3. A sulfonylglycine derivative represented by the formula (IV):
Q--SO.sub.2 NHCH.sub.2 CO--R (IV)
where R represents a hydroxy group, an alkoxy group or an amino group which may be substituted with an alkoxycarbonyl group, Q represents a thiazolyl group which may be substituted by one or more substituents which are the same or different and selected from the group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsufonyl group, an optionally protected hydroxy group other than a lower alkoxy group, an optionally protected amino group, and a carbamoyl group..]. .[.4. A sulfonylglycine derivative as claimed in claim 1 wherein
Q represents a pyridyl group which may be substituted..]. 5. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents an indolyl group which may be substituted.
A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a benzothiazolyl group which may be
substituted. 7. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a benzisothiazolyl group which may
be substituted. 8. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a coumarinyl group which
may be substituted. 9. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a chromonyl group which may
be substituted. 10. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a benzimidazolyl group
which may be substituted. 11. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a benzotriazolyl
group which may be substituted. 12. A sulfonylglycine derivative as claimed in claim .[.1.]. .Iadd.18 .Iaddend.wherein Q represents a
benzisoxazolyl group which may be substituted. .[.13. A sulfonylglycine derivative represented by the formula (IV):
Q--SO.sub.2 NHCH.sub.2 CO--R (IV)
wherein
R represents a hydroxy group, an alkoxy group or an amino group which may be substituted with an alkoxycarbonyl group, Q represents a furyl group, a pyridyl group, an indolyl group, a benzothiazolyl group, a benzisothiazolyl group, a benzothienyl group, a coumarinyl group, a chromonyl group, a benzimidazolyl group, a benzotriazolyl group or a benzisoxazolyl group any one of which may be substituted by one or more substituents which are the same or different and selected from a group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an optionally protected hydroxy group other than a lower alkoxy group, an optionally protected amino group, a carbamoyl group and a phenyl group,
or Q represents a benzo[b]furan-2-yl group which may be substituted by one or more substituents which are the same or different and are selected from the group consisting of a halogen atom, a cyano group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group,
a carbamoyl group and a phenyl group..]. 14. A sulfonylglycine derivative as claimed in claim .[.13.]. .Iadd.18.Iaddend., wherein Q represents a
furyl group, a benzothienyl group or a benzo[b]furan-2-yl group. 15. A sulfonylglycine derivative as claimed in claim 14, wherein Q represents a
benzo[b]thien-2-yl group which may b substituted. 16. A sulfonylglycine derivative as claimed in claim 14, wherein Q represents a
benzo[b]furan-2-yl group which may b substituted. 17. A sulfonylglycine derivative as claimed in claim 16, wherein the said substituents are 1 to
3 halogen atoms. .Iadd.18. A sulfonylglycine derivative represented by the formula (IV):
Q--SO.sub.2 NHCH.sub.2 CO--R (IV)
where R represents a hydroxy group, an alkoxy group or an amino group which may be substituted with an alkoxycarbonyl group, Q represents a furyl group, an indolyl group, a benzothiazolyl group, a benzisothiazolyl group, a benzothienyl group, a coumarinyl group, a chromonyl group, a benzimidazolyl group, a benzotriazolyl group or a benzisoxazolyl group any one of which may be substituted by one or more substituents which are the same or different and are selected from the group consisting of a halogen atom, a lower alkyl group, a nitro group, a cyano group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxy group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an optionally protected hydroxy group other than a lower alkoxy group, an optionally protected amino group, a carbamoyl group, and a phenyl group, or Q represents a benzo[b]furan-2-yl group which may be substituted by one or more substituents which are the same or different and are selected from the group consisting of a halogen atom, a cyano group, an optionally protected carboxymethyl group, a halogenated lower alkyl group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a carbamoyl group and a phenyl group. .Iaddend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/197,705 USRE35279E (en) | 1987-08-28 | 1994-02-17 | Hydantoin derivatives |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62-214549 | 1987-08-28 | ||
| JP62214549A JP2764262B2 (en) | 1987-08-28 | 1987-08-28 | Hydantoin derivative and pharmaceutical composition containing the same as active ingredient |
| US07/235,557 US4914099A (en) | 1987-08-28 | 1988-08-24 | Hydantoin derivatives as aldose reductase inhibitors |
| JP4342289 | 1989-02-25 | ||
| JP1-43422 | 1989-02-25 | ||
| US07/426,021 US5004751A (en) | 1987-08-28 | 1989-10-24 | Hydantoin derivatives |
| US07/644,632 US5232936A (en) | 1987-08-28 | 1991-01-23 | Hydantoin derivatives |
| US08/197,705 USRE35279E (en) | 1987-08-28 | 1994-02-17 | Hydantoin derivatives |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/426,021 Division US5004751A (en) | 1987-08-28 | 1989-10-24 | Hydantoin derivatives |
| US07/644,632 Reissue US5232936A (en) | 1987-08-28 | 1991-01-23 | Hydantoin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE35279E true USRE35279E (en) | 1996-06-18 |
Family
ID=26383179
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/426,021 Expired - Lifetime US5004751A (en) | 1987-08-28 | 1989-10-24 | Hydantoin derivatives |
| US07/644,632 Ceased US5232936A (en) | 1987-08-28 | 1991-01-23 | Hydantoin derivatives |
| US08/197,705 Expired - Lifetime USRE35279E (en) | 1987-08-28 | 1994-02-17 | Hydantoin derivatives |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/426,021 Expired - Lifetime US5004751A (en) | 1987-08-28 | 1989-10-24 | Hydantoin derivatives |
| US07/644,632 Ceased US5232936A (en) | 1987-08-28 | 1991-01-23 | Hydantoin derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US5004751A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187924B1 (en) * | 1997-11-12 | 2001-02-13 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| JP2003518122A (en) * | 1999-12-21 | 2003-06-03 | ジーピーアイ エヌアイエル ホールディングズ インコーポレーテッド | Hydantoin derivative compounds, pharmaceutical synthetic products and methods of using them |
| DE60315984T2 (en) * | 2002-05-17 | 2008-05-29 | Tibotec Pharmaceuticals Ltd. | SUBSTITUTED BENZOXOXOLSULFONAMIDES WITH BROAD-BONDED HIV-PROTEASE HAMMENDER EFFECT |
| US20040010024A1 (en) * | 2002-07-10 | 2004-01-15 | Howarth Jonathan N. | Particulate blends and compacted products formed therefrom, and the preparation thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3384643A (en) * | 1965-02-17 | 1968-05-21 | Upjohn Co | 1-hydrocarbylsulfonyl-2, 2-dichloro (ordialkoxy)-4, 5-imidazolidine diones |
| FR6097M (en) * | 1966-02-17 | 1968-06-10 | ||
| FR2308626A1 (en) * | 1975-04-22 | 1976-11-19 | Sumitomo Chemical Co | PROCESS FOR THE PREPARATION OF N'-SULFONYL-N '' - DIHALOPHENYLIMIDAZOLIDINEDIONES AND NEW PRODUCTS THUS OBTAINED, WITH MICROBICIDAL ACTIVITY AGAINST MUSHROOMS AND BACTERIA SPREADING IN INDUSTRIAL PRODUCTS |
| US4348519A (en) * | 1979-06-13 | 1982-09-07 | Hoffmann-La Roche Inc. | Thiazine derivatives |
| US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
| EP0187387A1 (en) * | 1984-12-29 | 1986-07-16 | Kaken Pharmaceutical Co., Ltd. | Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same |
| US4656169A (en) * | 1984-08-14 | 1987-04-07 | Pfizer Inc. | Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions |
| EP0251784A2 (en) * | 1986-07-02 | 1988-01-07 | American Home Products Corporation | Naphthalenylsulfonylimidazolidinediones and their thioxo analogs |
| US4791102A (en) * | 1986-01-24 | 1988-12-13 | Sanofi | Derivatives of the N α-arylsulphonylaminoacyl-p-amidinophenylalaninamides, their preparation process, their use as medicaments and the pharmaceutical compositions containing them |
| EP0355827A2 (en) * | 1988-08-24 | 1990-02-28 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives |
| EP0305947B1 (en) * | 1987-08-28 | 1992-07-29 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use |
-
1989
- 1989-10-24 US US07/426,021 patent/US5004751A/en not_active Expired - Lifetime
-
1991
- 1991-01-23 US US07/644,632 patent/US5232936A/en not_active Ceased
-
1994
- 1994-02-17 US US08/197,705 patent/USRE35279E/en not_active Expired - Lifetime
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3384643A (en) * | 1965-02-17 | 1968-05-21 | Upjohn Co | 1-hydrocarbylsulfonyl-2, 2-dichloro (ordialkoxy)-4, 5-imidazolidine diones |
| FR6097M (en) * | 1966-02-17 | 1968-06-10 | ||
| US3534022A (en) * | 1966-02-17 | 1970-10-13 | Dainippon Pharmaceutical Co | 1-sulfonyl-5,5-disubstituted hydantoins and processes for preparation thereof |
| FR2308626A1 (en) * | 1975-04-22 | 1976-11-19 | Sumitomo Chemical Co | PROCESS FOR THE PREPARATION OF N'-SULFONYL-N '' - DIHALOPHENYLIMIDAZOLIDINEDIONES AND NEW PRODUCTS THUS OBTAINED, WITH MICROBICIDAL ACTIVITY AGAINST MUSHROOMS AND BACTERIA SPREADING IN INDUSTRIAL PRODUCTS |
| US4056622A (en) * | 1975-04-22 | 1977-11-01 | Sumitomo Chemical Company, Limited | N-sulfonyl-N-dihalophenylimidazolidinediones |
| US4348519A (en) * | 1979-06-13 | 1982-09-07 | Hoffmann-La Roche Inc. | Thiazine derivatives |
| US4656169A (en) * | 1984-08-14 | 1987-04-07 | Pfizer Inc. | Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions |
| EP0187387A1 (en) * | 1984-12-29 | 1986-07-16 | Kaken Pharmaceutical Co., Ltd. | Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same |
| US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
| US4791102A (en) * | 1986-01-24 | 1988-12-13 | Sanofi | Derivatives of the N α-arylsulphonylaminoacyl-p-amidinophenylalaninamides, their preparation process, their use as medicaments and the pharmaceutical compositions containing them |
| EP0251784A2 (en) * | 1986-07-02 | 1988-01-07 | American Home Products Corporation | Naphthalenylsulfonylimidazolidinediones and their thioxo analogs |
| US4743611A (en) * | 1986-07-02 | 1988-05-10 | American Home Products Corp. | Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors |
| EP0305947B1 (en) * | 1987-08-28 | 1992-07-29 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use |
| EP0355827A2 (en) * | 1988-08-24 | 1990-02-28 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives |
Non-Patent Citations (50)
| Title |
|---|
| Bellemin et al., "Synthesis of Some Pyrazolo[4,3-e][1,2]-and Thiazolo[4,5-e][1,2]thiazine 1,1-Dioxide Derivatives", J. Heterocyclic Chem., 21, 1017 (1984), pp. 1017-1021. |
| Bellemin et al., Synthesis of Some Pyrazolo 4,3 e 1,2 and Thiazolo 4,5 e 1,2 thiazine 1,1 Dioxide Derivatives , J. Heterocyclic Chem., 21, 1017 (1984), pp. 1017 1021. * |
| Chemical Abstracts, vol. 101, 1984, Abstract No. 23906t. * |
| Chemical Abstracts, vol. 101, 1984, Abstract No. 38464w. * |
| Chemical Abstracts, vol. 102, 1985, Abstract No. 6355r. * |
| Chemical Abstracts, vol. 106, 1987, Abstract No. 119683x. * |
| Chemical Abstracts, vol. 106, 1987, Abstract No. 156145u. * |
| Chemical Abstracts, vol. 106, 1987, Abstract No. 156380s. * |
| Chemical Abstracts, vol. 106, 1987, Abstract No. 4857q. * |
| Chemical Abstracts, vol. 107, 1987, Abstract No. 58954h. * |
| Chemical Abstracts, vol. 107, 1987, Abstract No. 59037y. * |
| Chemical Abstracts, vol. 107, 1987, Abstract No. 7583d. * |
| Chemical Abstracts, vol. 107, 1987, Abstract No. 77727c. * |
| Chemical Abstracts, vol. 109, 1988, Abstract No. 129004c. * |
| Chemical Abstracts, vol. 109, 1988, Abstract No. 190818n. * |
| Chemical Abstracts, vol. 109, 1988, Abstract No. 211019y. * |
| Chemical Abstracts, vol. 109, 1988, Abstract No. 38244q. * |
| Chemical Abstracts, vol. 85, 1976, Abstract No. 63077f. * |
| Chemical Abstracts, vol. 87, 1977, Abstract No. 167930m. * |
| Chemical Abstracts, vol. 87, 1977, Abstract No. 68159k. * |
| Chemical Abstracts, vol. 90, 1979, Abstract No. 121208r. * |
| Chemical Abstracts, vol. 91, 1979, Abstract No. 5233s. * |
| Chemical Abstracts, vol. 94, 1981, Abstract No. 208890p. * |
| Chemical Abstracts, vol. 95, 1981, Abstract No. 168034z. * |
| Chemical Abstracts, vol. 95, No. 15, 1981, Abstract No. 132725m. * |
| Chemical Abstracts, vol. 97, 1982, Abstract No. 128022d. * |
| Chemical Abstracts, vol. 97, No. 1, 1982, Abstract No. 6774e. * |
| Chemical Abstracts, vol. 99, 1983, Abstract No. 116079f. * |
| El Naggar et al, Snythesis of Some Biologically Active Substituted Thiazole and Thiazoline Amino Acid Derivatives , Int. J. Peptide Protein Res., 19, 1982, pp. 408 412. * |
| El-Naggar et al, "Snythesis of Some Biologically Active Substituted Thiazole and Thiazoline-Amino Acid Derivatives", Int. J. Peptide Protein Res., 19, 1982, pp. 408-412. |
| Miwa et al., "Development of Potent Aldose Reductase Inhibitors", Biochemical Pharmacology, vol. 36, No. 17, pp. 2789-2794, 1987. |
| Miwa et al., "Hypoglycemic Activity of Aldose Reductase Inhibitor", Chem. Pharm. Bull., vol. 32, No. 5, pp. 2030-2032, 1984. |
| Miwa et al., "Improvement of Nerve Conduction Velocity in Mutant Diabetic Mice", Chem. Pharm. Bull., vol. 37, No. 6, pp. 1581-1582, 1989. |
| Miwa et al., "In Vivo Activities of Aldose Reductase Inhibitors", Biochemical Pharmacology, vol. 40, No. 2, pp. 303-307, 1990. |
| Miwa et al., Development of Potent Aldose Reductase Inhibitors , Biochemical Pharmacology, vol. 36, No. 17, pp. 2789 2794, 1987. * |
| Miwa et al., Hypoglycemic Activity of Aldose Reductase Inhibitor , Chem. Pharm. Bull., vol. 32, No. 5, pp. 2030 2032, 1984. * |
| Miwa et al., Improvement of Nerve Conduction Velocity in Mutant Diabetic Mice , Chem. Pharm. Bull., vol. 37, No. 6, pp. 1581 1582, 1989. * |
| Miwa et al., In Vivo Activities of Aldose Reductase Inhibitors , Biochemical Pharmacology, vol. 40, No. 2, pp. 303 307, 1990. * |
| Okuda, "Aldose Reductase Inhibitor", Patent Abstracts of Japan, vol. 7, No. 209 (C-186), 1983. JP-58-109418. |
| Okuda, "Hydantoin Derivative and Aldose Reductase Inhibitor", Patent Abstracts of Japan, vol. 11, No. 267 (C-443), 1987. JP 62-67075. |
| Okuda, "Hydantoin Derivative and Aldose Reductase Inhibitor", Patent Abstracts of Japan, vol. 12, No. 56 (C-477), 1988. JP 62-201873. |
| Okuda, Aldose Reductase Inhibitor , Patent Abstracts of Japan, vol. 7, No. 209 (C 186), 1983. JP 58 109418. * |
| Okuda, Hydantoin Derivative and Aldose Reductase Inhibitor , Patent Abstracts of Japan, vol. 11, No. 267 (C 443), 1987. JP 62 67075. * |
| Okuda, Hydantoin Derivative and Aldose Reductase Inhibitor , Patent Abstracts of Japan, vol. 12, No. 56 (C 477), 1988. JP 62 201873. * |
| Saito et al., "Synthesis and Antiinflammatory Activity of Pyrido[4,3-e]-1,2-thiazine-3-carboxamide Derivatives", Yakugaku Zasshi 106, (1986), pp. 1008-1016. |
| Saito et al., Synthesis and Antiinflammatory Activity of Pyrido 4,3 e 1,2 thiazine 3 carboxamide Derivatives , Yakugaku Zasshi 106, (1986), pp. 1008 1016. * |
| Zawisza et al., "Synthesis and Properties of 2H-4-Hydroxy-2,5,7-trimethylpyrido[3,2-e]-1,2-thiazine-1,1-dioxide-3-carboxamides", Il Farmaco Ed. Sci., 41, (1986), pp. 892-898. |
| Zawisza et al., "Synthesis and Properties of Some Derivatives of 2H-4,6-Dimethylpyrido[3,2-d]Isothiazoline-3-one-1,1-dioxide", Il Farmaco Ed. Sci., 41, (1986), pp. 676-883. |
| Zawisza et al., Synthesis and Properties of 2H 4 Hydroxy 2,5,7 trimethylpyrido 3,2 e 1,2 thiazine 1,1 dioxide 3 carboxamides , Il Farmaco Ed. Sci., 41, (1986), pp. 892 898. * |
| Zawisza et al., Synthesis and Properties of Some Derivatives of 2H 4,6 Dimethylpyrido 3,2 d Isothiazoline 3 one 1,1 dioxide , Il Farmaco Ed. Sci., 41, (1986), pp. 676 883. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US5004751A (en) | 1991-04-02 |
| US5232936A (en) | 1993-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5189049A (en) | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | |
| US4948796A (en) | Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient | |
| US5304556A (en) | Benza-triazinone derivatives | |
| DE69830504T2 (en) | ANTITROMOMBOTIC MEANS | |
| US5670532A (en) | Pyrazolyl derivatives for the treatment of inflammation | |
| US6140504A (en) | Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
| US5273974A (en) | Condensed heterocyclic compounds, their production and use | |
| US5990139A (en) | Thiazolidinedione derivatives or salts thereof and pharmaceutical compositions containing the same | |
| US5811429A (en) | Bicyclic heterocyclic compounds | |
| US5525604A (en) | 4-aminopyrimidine derivatives | |
| US6069162A (en) | Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production | |
| US4808711A (en) | Cephalosporin derivatives | |
| US5731340A (en) | Glycinamide derivatives, processes for their preparation and medicines containing them | |
| US6077840A (en) | Tetrahydrobenzindolone derivatives | |
| US4914099A (en) | Hydantoin derivatives as aldose reductase inhibitors | |
| JP2003128672A (en) | Diacid-substituted heteroaryl derivatives as matrixmetalloproteinase inhibitor | |
| US5011839A (en) | 3(2H)pyridazinones for antagonistic agent against srs-a | |
| US4725616A (en) | 1,3-dicarboxamide-oxindoles as antiinflammatory agents | |
| US5952320A (en) | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion | |
| EP0299457B1 (en) | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | |
| USRE35279E (en) | Hydantoin derivatives | |
| US5693650A (en) | 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives | |
| US4552969A (en) | 3-Alkanoyl benzothiazoline compounds useful for treating cardiovascular disease | |
| US4791129A (en) | 1,3-dicarboxamidooxindoles as analgesic and antiinflammatory agents | |
| US4124376A (en) | Herbicide compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |